<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id><journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id><journal-id journal-id-type="publisher-id">nar</journal-id><journal-id journal-id-type="hwp">nar</journal-id><journal-title-group><journal-title>Nucleic Acids Research</journal-title></journal-title-group><issn pub-type="ppub">0305-1048</issn><issn pub-type="epub">1362-4962</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22735708</article-id><article-id pub-id-type="pmc">3479160</article-id><article-id pub-id-type="doi">10.1093/nar/gks615</article-id><article-id pub-id-type="publisher-id">gks615</article-id><article-categories><subj-group subj-group-type="heading"><subject>Methods Online</subject></subj-group></article-categories><title-group><article-title>Co-clustering phenome&#x02013;genome for phenotype classification and disease gene discovery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hwang</surname><given-names>TaeHyun</given-names></name><xref ref-type="aff" rid="gks615-AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Atluri</surname><given-names>Gowtham</given-names></name><xref ref-type="aff" rid="gks615-AFF1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>MaoQiang</given-names></name><xref ref-type="aff" rid="gks615-AFF1"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dey</surname><given-names>Sanjoy</given-names></name><xref ref-type="aff" rid="gks615-AFF1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Changjin</given-names></name><xref ref-type="aff" rid="gks615-AFF1"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Vipin</given-names></name><xref ref-type="aff" rid="gks615-AFF1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuang</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="gks615-AFF1"><sup>2</sup></xref><xref ref-type="corresp" rid="gks615-COR1">*</xref></contrib></contrib-group><aff id="gks615-AFF1"><sup>1</sup>Bioinformatics core at Masonic Cancer Center, <sup>2</sup>Department of Computer Science and Engineering, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA, <sup>3</sup>College of Software, Nankai University, Tianjin, 300071, China and <sup>4</sup>Computational Biomedicine Division, Department of Medicine, Boston University, MA 02118, USA</aff><author-notes><corresp id="gks615-COR1">*To whom correspondence should be addressed. Tel: <phone>+1 612 6247820</phone>; Fax: <fax>+1 612 6250572</fax>; Email: <email>kuang@cs.umn.edu</email></corresp></author-notes><!--For NAR both ppub and collection dates generated for PMC processing 1/27/05 beck--><pub-date pub-type="collection"><month>10</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>6</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>40</volume><issue>19</issue><fpage>e146</fpage><lpage>e146</lpage><history><date date-type="received"><day>23</day><month>3</month><year>2012</year></date><date date-type="rev-recd"><day>29</day><month>5</month><year>2012</year></date><date date-type="accepted"><day>31</day><month>5</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2012. Published by Oxford University Press.</copyright-statement><copyright-year>2012</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Understanding the categorization of human diseases is critical for reliably identifying disease causal genes. Recently, genome-wide studies of abnormal chromosomal locations related to diseases have mapped &#x0003e;2000 phenotype&#x02013;gene relations, which provide valuable information for classifying diseases and identifying candidate genes as drug targets. In this article, a regularized non-negative matrix tri-factorization (R-NMTF) algorithm is introduced to co-cluster phenotypes and genes, and simultaneously detect associations between the detected phenotype clusters and gene clusters. The R-NMTF algorithm factorizes the phenotype&#x02013;gene association matrix under the prior knowledge from phenotype similarity network and protein&#x02013;protein interaction network, supervised by the label information from known disease classes and biological pathways. In the experiments on disease phenotype&#x02013;gene associations in OMIM and KEGG disease pathways, R-NMTF significantly improved the classification of disease phenotypes and disease pathway genes compared with support vector machines and Label Propagation in cross-validation on the annotated phenotypes and genes. The newly predicted phenotypes in each disease class are highly consistent with human phenotype ontology annotations. The roles of the new member genes in the disease pathways are examined and validated in the protein&#x02013;protein interaction subnetworks. Extensive literature review also confirmed many new members of the disease classes and pathways as well as the predicted associations between disease phenotype classes and pathways.</p></abstract><counts><page-count count="16"/></counts></article-meta></front><body><sec><title>INTRODUCTION</title><p>Phenotypes, the observable characteristics (traits) of an organism, are believed to be determined by genetic materials (DNAs) under environmental influences (<xref ref-type="bibr" rid="gks615-B1">1</xref>,<xref ref-type="bibr" rid="gks615-B2">2</xref>). The key to achieving desired phenotypes such as favorable disease treatment outcomes lies in the understanding of the relation between phenotypes and the biological roles of genes (<xref ref-type="bibr" rid="gks615-B3 gks615-B4 gks615-B5">3&#x02013;5</xref>). In the past two decades, promising bio-technologies such as microarray-based profiling (<xref ref-type="bibr" rid="gks615-B6 gks615-B7 gks615-B8 gks615-B9">6&#x02013;9</xref>) and second generation sequencing (<xref ref-type="bibr" rid="gks615-B10">10</xref>,<xref ref-type="bibr" rid="gks615-B11">11</xref>) were developed to hunt for potential phenotype&#x02013;gene associations. Currently, in the most comprehensive disease, phenotype&#x02013;gene relation database, Online Mendelian Inheritance in Man (OMIM) (<xref ref-type="bibr" rid="gks615-B2">2</xref>), nearly 2000 confirmed relations between around 6000 phenotypes and over 12&#x02009;000 genes are documented. This knowledge base provides a new phenome (the collection of all phenotypes) perspective to study human diseases and their molecular mechanisms. Although most previous studies focused on predicting new disease phenotype&#x02013;gene relations with OMIM data (<xref ref-type="bibr" rid="gks615-B12 gks615-B13 gks615-B14 gks615-B15 gks615-B16 gks615-B17 gks615-B18 gks615-B19">12&#x02013;19</xref>), we propose to cluster phenotypes and find gene modules associated with the phenotype clusters by integrating OMIM phenotype&#x02013;gene relations with disease phenotype similarity network and the human gene interaction network as well as exiting disease categorization and molecular pathways. To effectively use all the sources of information, we design regularized non&#x02013;negative matrix tri-factorization (R-NMTF) algorithms to tri-factorize the binary matrix of phenotype&#x02013;gene relations into phenotype clusters, gene clusters and an association matrix representing the associations between phenotype clusters and the gene clusters (<xref ref-type="fig" rid="gks615-F1">Figure 1</xref>). Since the matrix of known phenotype&#x02013;gene relations is very sparse, constraints constructed from the prior knowledge and the phenotype/gene labels are introduced to regularize the NMTF models.<fig id="gks615-F1" position="float"><label>Figure 1.</label><caption><p>NMTF of disease phenotype&#x02013;gene associations. The phenotype&#x02013;gene association matrix <italic>X</italic> is factorized into products of three matrices, phenotype cluster membership <italic>F</italic>, gene cluster membership <italic>G</italic> and phenotype cluster&#x02013;gene cluster association <italic>S</italic> for supervised co-clustering of phenotypes and genes. Label information for the disease classes and the pathways are available for a small number of phenotypes and genes. Prior knowledge is also introduced from phenotype similarity network and gene network. For better visualization, different colors are used to distinguish the phenotypes and the genes in different clusters.</p></caption><graphic xlink:href="gks615f1p"/></fig></p><p>Current classification of human disease is mainly based on observational correlation between pathological analysis and clinical syndromes (<xref ref-type="bibr" rid="gks615-B20">20</xref>), and more recently, by text mining of clinical records and synopsis (<xref ref-type="bibr" rid="gks615-B21">21</xref>). An accurate classification of human diseases based on its phenotypic and molecular basis will help to establish syndromic patterns for selecting phenotypes to consider in diagnosis. Existing phenotype clustering approaches cluster phenotypes based on only text descriptions and synopsis (<xref ref-type="bibr" rid="gks615-B22 gks615-B23 gks615-B24">22&#x02013;24</xref>) or shared disease genes (<xref ref-type="bibr" rid="gks615-B25">25</xref>), which do not fully reflect both phenotypic and genetic basis of the disease phenotypes. R-NMTF integrates various sources of phenotypic and genomic data as well as prior knowledge to perform supervised co-clustering of phenotypes and genes simultaneously. R-NMTF is the first of its kind that effectively discovers disease classes based on the molecular underpinnings of the phenotypes and the molecular interactions in a network. This approach implements the philosophy of network-based medicine (<xref ref-type="bibr" rid="gks615-B26">26</xref>), which is believed to be the promising approach for generating the next generation of disease categorization (<xref ref-type="bibr" rid="gks615-B20">20</xref>). The R-NMTF-based co-clustering also naturally induces the associations between the phenotype clusters and gene clusters, which provides a global pathway activity view of human disease classes for understanding the unique as well as common underlying molecular mechanisms of diseases.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>In this section, we first describe the notations for the data of disease phenotypes, genes and their associations. We then review NMTF and introduce the framework of R-NMTF for co-clustering phenotypes and genes. We also outline the multiplicative update algorithm for solving the R-NMTF model.</p><sec><title>Notations</title><p>The notations and definitions used in the article are specified in <xref ref-type="table" rid="gks615-T1">Table 1</xref>. We denote the OMIM phenotype&#x02013;gene associations by a <italic>m</italic> by <italic>n</italic> binary matrix <italic>X</italic> with 1 for known associations and 0 otherwise. The objective is to derive phenotype clusters (<italic>F</italic>) and find their association (<italic>S</italic>) with gene clusters (<italic>G</italic>) based on <italic>X</italic> (<xref ref-type="fig" rid="gks615-F1">Figure 1</xref>). <italic>F</italic> and <italic>G</italic> are non-negative matrices representing the soft memberships of each gene/phenotype against the <italic>k</italic><sub>1</sub> phenotype clusters or the <italic>k</italic><sub>2</sub> gene clusters. To perform more reliable phenotype clustering in a supervised setting, we use the partial phenotype annotations by (<xref ref-type="bibr" rid="gks615-B25">25</xref>) represented by a binary matrix <italic>F</italic><sup>0</sup> with 1 for the known class memberships. Similarly, KEGG pathways (<xref ref-type="bibr" rid="gks615-B27">27</xref>) are also included in a binary matrix <italic>G</italic><sup>0</sup> to guide gene clustering. Note that, since training samples are not required for each disease category to classify the phenotypes in the model, we use the word &#x02018;co-clustering&#x02019; instead of &#x02018;classification&#x02019; or &#x02018;semi-supervised learning&#x02019; for the learning problem although in the experiments, we only focused on recovering the 21 disease categories with at least one OMIM disease phenotype. Finally, a phenotype similarity network <italic>M</italic> (<xref ref-type="bibr" rid="gks615-B21">21</xref>) and the gene interaction network <italic>N</italic> were also introduced to capture modular relations among phenotypes and genes. <italic>M</italic> and <italic>N</italic> contain edges weighted by the degree of similarity between phenotypes or the confidence of interaction between genes, respectively.
<table-wrap id="gks615-T1" position="float"><label>Table 1.</label><caption><p>Notations</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th align="left" rowspan="1" colspan="1">Notation</th><th align="left" rowspan="1" colspan="1">Definition</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1"><italic>m</italic></td><td rowspan="1" colspan="1">Number of disease phenotypes</td></tr><tr><td rowspan="1" colspan="1"><italic>n</italic></td><td rowspan="1" colspan="1">Number of genes</td></tr><tr><td rowspan="1" colspan="1"><italic>k</italic><sub>1</sub></td><td rowspan="1" colspan="1">Number of phenotype clusters (e.g. classes)</td></tr><tr><td rowspan="1" colspan="1"><italic>k</italic><sub>2</sub></td><td rowspan="1" colspan="1">Number of gene clusters (e.g. pathways)</td></tr><tr><td rowspan="1" colspan="1"><italic>X</italic></td><td rowspan="1" colspan="1">Disease phenotype&#x02013;gene association matrix (<italic>m</italic>&#x02009;&#x000d7;&#x02009;<italic>n</italic>)</td></tr><tr><td rowspan="1" colspan="1"><italic>F</italic></td><td rowspan="1" colspan="1">Phenotype cluster membership (<italic>m</italic>&#x02009;&#x000d7;&#x02009;<italic>k</italic><sub>1</sub>)</td></tr><tr><td rowspan="1" colspan="1"><italic>S</italic></td><td rowspan="1" colspan="1">Phenotype cluster&#x02013;gene cluster association Matrix (<italic>k</italic><sub>1</sub>&#x02009;&#x000d7;&#x02009;<italic>k</italic><sub>2</sub>)</td></tr><tr><td rowspan="1" colspan="1"><italic>G</italic></td><td rowspan="1" colspan="1">Gene cluster membership (<italic>n</italic>&#x02009;&#x000d7;&#x02009;<italic>k</italic><sub>2</sub>)</td></tr><tr><td rowspan="1" colspan="1"><italic>F</italic><sup>0</sup></td><td rowspan="1" colspan="1">Annotated phenotype cluster membership (<italic>m</italic>&#x02009;&#x000d7;&#x02009;<italic>k</italic><sub>1</sub>)</td></tr><tr><td rowspan="1" colspan="1"><italic>G</italic><sup>0</sup></td><td rowspan="1" colspan="1">Annotated gene cluster membership (<italic>n</italic>&#x02009;&#x000d7;&#x02009;<italic>k</italic><sub>2</sub>)</td></tr><tr><td rowspan="1" colspan="1"><italic>M</italic></td><td rowspan="1" colspan="1">Disease phenotype similarity network (<italic>m</italic>&#x02009;&#x000d7;&#x02009;<italic>m</italic>)</td></tr><tr><td rowspan="1" colspan="1"><italic>N</italic></td><td rowspan="1" colspan="1">Gene interaction network (<italic>n</italic>&#x02009;&#x000d7;&#x02009;<italic>n</italic>)</td></tr></tbody></table></table-wrap></p></sec><sec><title>Non-negative matrix tri-factorization</title><p>Non-negative matrix factorization (NMF) was proposed by (<xref ref-type="bibr" rid="gks615-B28">28</xref>,<xref ref-type="bibr" rid="gks615-B29">29</xref>) as an alternative to principle component analysis and vector quantization for parts-based decomposition of a data matrix. NMF has been applied to solve various bioinformatics problems such as identifying gene clusters (<xref ref-type="bibr" rid="gks615-B30 gks615-B31 gks615-B32">30&#x02013;32</xref>), bi-clustering (<xref ref-type="bibr" rid="gks615-B33">33</xref>) and identifying cancer tumor categories (<xref ref-type="bibr" rid="gks615-B34">34</xref>) in gene expression data analysis, and finding modules in protein&#x02013;protein interaction (PPI) network (<xref ref-type="bibr" rid="gks615-B35">35</xref>).</p><p>By imposing the orthogonality on the two factorized matrices, (<xref ref-type="bibr" rid="gks615-B36">36</xref>) proposed a framework to perform NMTF as <italic>X</italic>&#x02009;&#x02243;&#x02009;<italic>FSG</italic><sup><italic>T</italic></sup> under the constraints <italic>F</italic><sup><italic>T</italic></sup><italic>F</italic>&#x02009;=&#x02009;<bold>1</bold> and <italic>G</italic><sup><italic>T</italic></sup><italic>G</italic>&#x02009;=&#x02009;<bold>1</bold>. This framework has the advantage of simultaneously clustering the columns and rows, and finding a condense representation of the data matrix by the row clusters and the column clusters, which can also be considered as associations between row clusters and column clusters. For co-clustering phenotypes and genes, the NMTF approach provides novel insights into the phenotype&#x02013;gene associations beyond clustering and decomposition.</p></sec><sec><title>Regularization by phenotype and gene labels</title><p>To cluster phenotypes and genes based on their associations, we adopt supervised NMTF proposed for finding associations between document clusters and word clusters in text categorization (<xref ref-type="bibr" rid="gks615-B37">37</xref>,<xref ref-type="bibr" rid="gks615-B38">38</xref>). We use manually labeled phenotype clusters as the phenotype label <italic>F</italic><sup>0</sup> and gene clusters from existing pathway database as the gene label <italic>G</italic><sup>0</sup>, and simultaneously cluster phenotypes and genes with tri-factorization as illustrated in <xref ref-type="fig" rid="gks615-F1">Figure 1</xref>. The following optimization framework can be solved to achieve the goal:
<disp-formula id="gks615-M1"><label>(1)</label><graphic xlink:href="gks615m1"/></disp-formula>
In equation (<xref ref-type="disp-formula" rid="gks615-M1">1</xref>), the first term is the NMTF of <italic>X</italic>, and the second and the third terms are the fitting penalties to keep the new cluster assignment consistent with the known phenotype and gene cluster labels. These two terms are introduced as a supervised way of minimizing the squared loss between the predicted phenotype cluster assignment <italic>F</italic> and the initial phenotype cluster assignment <italic>F</italic><sup>0</sup>, and between the predicted gene cluster assignment <italic>G</italic> and the initial gene cluster assignment <italic>G</italic><sup>0</sup>. Specifically, the phenotype clusters are taken from the 21 disease classes manually curated by (<xref ref-type="bibr" rid="gks615-B25">25</xref>), in which 872 disease phenotypes are assigned to 21 classes. The gene clusters are derived from the genes in KEGG pathways (<xref ref-type="bibr" rid="gks615-B27">27</xref>). The information of the labeled phenotypes and genes provides the useful guidance to learning more accurate co-clustering.</p><p>A limitation of the approach in equation (<xref ref-type="disp-formula" rid="gks615-M1">1</xref>) is the low coverage and the sparsity of the disease gene association matrix used to cluster phenotypes and genes. The known disease&#x02013;gene association only cover a small fraction of phenotypes and genes (one-third of the phenotypes and 5% of the genes), with very few associations between them (less than one association per phenotype/gene). Moreover, the phenotype cluster annotations and KEGG pathways also only provide a low coverage of around 15% phenotypes and one-fourth of the genes. The statistics simply suggest that with this model only a very small fraction of phenotypes and genes could be clustered properly.</p></sec><sec><title>Regularization by graph Laplacians</title><p>To address the above problem, we design R-NMTF to incorporate the prior knowledge in the phenotype similarity network and the PPI network (<xref ref-type="fig" rid="gks615-F1">Figure 1</xref>) to cluster phenotypes and genes with matrix tri-factorization. Given the phenotype similar network <italic>M</italic> and the PPI network <italic>N</italic>, the following optimization problem is formulated for the purpose:
<disp-formula id="gks615-M2"><label>(2)</label><graphic xlink:href="gks615m2"/></disp-formula>
where <italic>D</italic><sub><italic>M</italic></sub> is the diagonal matrix with the row summation of matrix <italic>M</italic> on the diagonal and <italic>D</italic><sub><italic>N</italic></sub> is similarly defined from <italic>N</italic>. In this equation, the first three terms are identical to those in equation (<xref ref-type="disp-formula" rid="gks615-M1">1</xref>). The fourth and fifth terms introduce the phenotype similarity network and the PPI network as prior knowledge to guide the clustering of the phenotypes and the genes. These two terms are called smoothness terms, which encourage the connected nodes (phenotypes/genes) in a graph to be assigned to the same cluster. Specifically, the term tr(<italic>F</italic><sup><italic>T</italic></sup>(<italic>D</italic><sub><italic>M</italic></sub>&#x02009;&#x02212;&#x02009;<italic>M</italic>)&#x02009;<italic>F</italic>) requires that the phenotype clusters identified by NMTF are also densely connected in the phenotype network, and similarly for tr(<italic>G</italic><sup><italic>T</italic></sup> (<italic>D</italic><sub><italic>N</italic></sub>&#x02009;&#x02212;&#x02009;<italic>N</italic>)<italic>G</italic>). <italic>D</italic><sub><italic>M</italic></sub>&#x02009;&#x02212;&#x02009;<italic>M</italic> and <italic>D</italic><sub><italic>N</italic></sub>&#x02009;&#x02212;&#x02009;<italic>N</italic> are known as the Laplacian matrices of the graphs, which are positive semi-definite (<xref ref-type="bibr" rid="gks615-B39">39</xref>).
<statement><title>Algorithm 1</title><p>Regularized Non-negative Matrix Tri-factorization</p><p><bold>INPUT:</bold>
<italic>X</italic>, <italic>F</italic><sup>0</sup>, <italic>G</italic><sup>0</sup>, <italic>L</italic><sub><italic>M</italic></sub>, <italic>L</italic><sub><italic>N</italic></sub>, parameters &#x003b1;, &#x003b2;, &#x003b3;, and &#x003bb;, maximum interation <italic>T</italic></p><p><bold>OUTPUT:</bold>
<italic>F</italic>, <italic>G</italic>, <italic>S</italic></p><p><bold>while</bold> not converged and <italic>t</italic>&#x02009;&#x02264;&#x02009;<italic>T</italic> do
<list list-type="order"><list-item><p>Update <inline-formula><inline-graphic xlink:href="gks615i1.jpg"/></inline-formula>.</p></list-item><list-item><p>Normalize <inline-formula><inline-graphic xlink:href="gks615i2.jpg"/></inline-formula></p></list-item><list-item><p>Update <inline-formula><inline-graphic xlink:href="gks615i3.jpg"/></inline-formula>.</p></list-item><list-item><p>Normalize <inline-formula><inline-graphic xlink:href="gks615i4.jpg"/></inline-formula>.</p></list-item><list-item><p>Compute <inline-formula><inline-graphic xlink:href="gks615i5.jpg"/></inline-formula>.</p></list-item></list></p><p><bold>end while</bold></p></statement></p></sec><sec><title>Multiplicative update algorithms</title><p>We extend the optimization algorithms for the original NMTF to handle the four additional penalty terms in equation (<xref ref-type="disp-formula" rid="gks615-M2">2</xref>). The alternative iterative scheme to solve the problem with respect to one variable while fixing the other variables are described.</p><sec><title>Computation of F</title><p>If we fix variables <italic>S</italic> and <italic>G</italic>, solving equation (<xref ref-type="disp-formula" rid="gks615-M2">2</xref>) with respect to <italic>F</italic> is equivalent to minimizing the following function:
<disp-formula><graphic xlink:href="gks615u1"/></disp-formula>
subject to <inline-formula><inline-graphic xlink:href="gks615i6.jpg"/></inline-formula>, where <italic>L</italic><sub><italic>M</italic></sub> is <italic>D</italic><sub><italic>M</italic></sub>&#x02009;&#x02212;&#x02009;<italic>M</italic>.</p><p>The differentiation of <italic>L</italic> with respect to <italic>F</italic> is
<disp-formula><graphic xlink:href="gks615u2"/></disp-formula>
The multiplicative update rule is
<disp-formula><graphic xlink:href="gks615u3"/></disp-formula>
To satisfy the equality constrain, we normalize <italic>F</italic> as
<disp-formula><graphic xlink:href="gks615u4"/></disp-formula></p></sec><sec><title>Computation of G</title><p>If we fix variables <italic>S</italic> and <italic>F</italic>, solving equation (<xref ref-type="disp-formula" rid="gks615-M2">2</xref>) with respect to <italic>G</italic> is equivalent to minimizing the function,
<disp-formula><graphic xlink:href="gks615u5"/></disp-formula>
subject to <inline-formula><inline-graphic xlink:href="gks615i7.jpg"/></inline-formula>, where <italic>L</italic><sub><italic>N</italic></sub> is <italic>D</italic><sub><italic>N</italic></sub>&#x02009;&#x02212;&#x02009;<italic>N</italic>.</p><p>The differentiation of <italic>L</italic> with respect to <italic>G</italic> is
<disp-formula><graphic xlink:href="gks615u6"/></disp-formula>
The multiplicative update rule is
<disp-formula><graphic xlink:href="gks615u7"/></disp-formula>
To satisfy the equality constrain, we normalize <italic>G</italic> as
<disp-formula><graphic xlink:href="gks615u8"/></disp-formula></p></sec><sec><title>Computation of S</title><p>After <italic>F</italic> and <italic>G</italic> are computed, solving equation (<xref ref-type="disp-formula" rid="gks615-M2">2</xref>) with respect to <italic>S</italic> is equivalent to minimizing the following function:
<disp-formula><graphic xlink:href="gks615u9"/></disp-formula>
The differentiation of <italic>L</italic> with respect to <italic>S</italic> is
<disp-formula><graphic xlink:href="gks615u10"/></disp-formula>
The multiplicative update rule is
<disp-formula><graphic xlink:href="gks615u11"/></disp-formula></p><p>The complete R-NMTF algorithm is outlined in Algorithm 1. Since the updating steps for <italic>F</italic>, <italic>S</italic> and <italic>G</italic> are non-increasing, the objective function will decrease until a lower bound is reached. Empirically, the algorithm converges fast within 100 iterations in the experiments.</p></sec></sec></sec><sec><title>EXPERIMENTS</title><p>To evaluate the performance of supervised co-clustering of phenotypes and genes, R-NMTF was applied to classifying OMIM human disease phenotypes and KEGG disease pathway genes with leave-one-out cross-validation. R-NMTF was compared with several baseline methods, including support vector machines (SVMs), Label Propagation (LP) and a NMTF model without network regularization defined in equation (<xref ref-type="disp-formula" rid="gks615-M1">1</xref>). R-NMTF was then applied to classify unannotated OMIM disease phenotypes and identify new member genes of KEGG disease pathways. The predictions were verified and analyzed by comparison with human phenotype ontology (HPO) and literature survey.</p><sec><title>Data preparation</title><p>We collected the disease phenotype&#x02013;gene associations in OMIM, which consist of the associations between 1284 disease phenotypes and 1777 disease genes. We also collected 200 KEGG pathways, which contain 4128 genes in total, from molecular signature database (<xref ref-type="bibr" rid="gks615-B40">40</xref>). We obtained the human protein-protein interaction (PPI) network from HPRD (<xref ref-type="bibr" rid="gks615-B41">41</xref>). The PPI network contains 76232 binary undirected interactions between 9667 genes. We obtained the phenotype similarity network from (<xref ref-type="bibr" rid="gks615-B21">21</xref>). The phenotype similarity network is an undirected graph with 5080 vertices representing OMIM disease phenotypes, and edges weighted by a number in [0,1]. The edge weights measure the similarity between phenotypes by their overlap in the text and the clinical synopsis in OMIM records, calculated by text mining (<xref ref-type="bibr" rid="gks615-B21">21</xref>).</p><p>In the leave-one-out cross-validation, after preprocessing (removing the phenotypes classified as multiple and unclassified, removing disease phenotypes not present in both the disease phenotype&#x02013;gene associations and the phenotype similarity network and removing genes not present in both the disease phenotype&#x02013;gene associations and the PPI network), we generated a dataset containing 590 disease phenotypes in 20 disease classes (<xref ref-type="bibr" rid="gks615-B25">25</xref>) and 7997 genes in 200 gene pathways. This dataset was used in leave-one-out cross-validation on disease phenotype classification and disease pathway gene discovery.</p><p>To further evaluate R-NMTF with more phenotypes and other independent phenotype annotations, we generated another larger dataset containing 1325 disease phenotypes with at least one known causal gene in OMIM. Among the 1325 disease phenotypes, 501 disease phenotypes intersect with the labeled disease phenotypes in the first dataset and the rest 824 disease phenotypes are unlabeled. Our task in this experiment is to perform a supervised clustering to assign the 824 unannotated disease phenotypes to the 20 disease classes.</p></sec><sec><title>Baselines and parameter tuning</title><p>Four baselines were introduced for comparison with R-NMTF, SVMs with linear kernel and radial basis kernel, LP and the NMTF model defined in equation (<xref ref-type="disp-formula" rid="gks615-M1">1</xref>) without the prior knowledge from the phenotype network and the PPI network (named NMTF). The SVMs used a binary vector representing the disease genes of each phenotype as the features for classification (<xref ref-type="bibr" rid="gks615-B25">25</xref>). We also tested SVMs with the similarity scores in the phenotype similarities network as features for classification. Since the results are close to random, we did not report them in the experiments. We also compared R-NMTF with a semi-supervised learning method, LP, which uses the disease similarity network and the PPI network for disease phenotype classification and disease gene discovery, respectively (<xref ref-type="bibr" rid="gks615-B42">42</xref>). The hyper-parameters (&#x003b1; and &#x003b2; for NMTF; &#x003b1;, &#x003b2;, &#x003b3; and &#x003bb; for R-NMTF and <italic>C</italic> and &#x003c3; for SVMs) were chosen by a grid search in {10<sup>&#x02212;3</sup>, 10<sup>&#x02212;2</sup>, 10<sup>&#x02212;1</sup>, 1, 10, 100}. The hyper-parameter &#x003b1; for LP was chosen by a grid search in {0.1, 0.3, 0.5, 0.7, 0.9}. More analysis of parameter tuning is described in the <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkr615/DC1">supplementary Table S1 and S2</ext-link>.</p><p>In the leave-one-out cross-validation on the 590 labeled phenotypes in disease phenotype classification, we held out one phenotype as the test case to be classified by all the compared methods. The performance is measured by the rank of the true disease class among the 20 target classes ranked by the corresponding classification scores generated by a classification method. Similarly, in the leave-one-out cross-validation for disease gene discovery on the same data, we held out one gene in a KEGG disease pathway as the test case to be classified by all the compared methods. Since one gene could belong to multiple disease pathways, the performance is measured by the area under the curve of receiver operating characteristic (AUC). Since leave-one-out cross-validation usually gives less overfitting bias, we reported the results with the best parameters for all the methods in the experiments on both disease phenotype classification and disease gene discovery.</p></sec><sec><title>Performance of disease phenotype classification in leave-one-out cross-validation</title><p>The average ranking performance of the compared methods are reported in <xref ref-type="table" rid="gks615-T2">Table 2</xref> and <xref ref-type="fig" rid="gks615-F2">Figure 2</xref>. On average, R-NMTF were able to rank the target class at around third out of the 20 classes, while the other methods performed worse. To further assess the statistical significance of the difference in the performance between R-NMTF and the baselines, we also report the pairwise comparison of each test case and performed a Wilconsin test on the difference of the ranks in <xref ref-type="table" rid="gks615-T2">Table 2</xref>. The <italic>P</italic>-values suggest that R-NMTF performed significantly better than the baselines. <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkr615/DC1">Supplementary Figure S1</ext-link> visualizes the pairwise comparison between R-NMTF and the baselines by scatter plot. Many more cases appeared in the top left triangle indicating a better ranking by R-NMTF. LP performed worse than R-NMTF but better than SVMs and NMTF. The observation indicates that the global structural information in the phenotype similarity network provides substantial information on phenotype classes. To further understand the classification performance in each disease class, we show in <xref ref-type="table" rid="gks615-T3">Table 3</xref> the classification performance for the phenotypes by disease classes. R-NMTF outperformed all the baseline methods in 11 disease classes. In some of the small classes such as &#x02018;ear, nose, throat&#x02019;, &#x02018;nutritional&#x02019; and &#x02018;respiratory&#x02019;, less relations among the training points are available for R-NMTF to improve classification.<fig id="gks615-F2" position="float"><label>Figure 2.</label><caption><p>Performance of phenotype classification in leave-one-out cross-validation. In this plot, the <italic>x</italic>-axis represents the cutoffs of the rank of the target disease class out of the 20 classes. The <italic>y</italic>-axis represents the faction of phenotypes with their target disease class ranked within a certain cutoff. For example, R-NMTF ranked the target class of &#x0003e;60% of the phenotypes within Rank 2, while the other methods only ranked around or &#x0003c;50% within the same rank cutoff.</p></caption><graphic xlink:href="gks615f2p"/></fig>
<table-wrap id="gks615-T2" position="float"><label>Table 2.</label><caption><p>Performance of phenotype classification in leave-one-out cross-validation</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Compared methods</th><th rowspan="1" colspan="1">Avg. rank</th><th rowspan="1" colspan="1">win/draw/loss (<italic>P</italic>-value)</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">R-NMTF versus NMTF</td><td rowspan="1" colspan="1"><bold>3.124</bold> versus 5.590</td><td rowspan="1" colspan="1">300/154/136 (4.617e&#x02212;13)</td></tr><tr><td rowspan="1" colspan="1">versus SVM-linear</td><td rowspan="1" colspan="1">versus 6.103</td><td rowspan="1" colspan="1">308/154/128 (3.693e&#x02212;12)</td></tr><tr><td rowspan="1" colspan="1">versus SVM-rbf</td><td rowspan="1" colspan="1">versus 5.037</td><td rowspan="1" colspan="1">268/213/109 (1.497e&#x02212;4)</td></tr><tr><td rowspan="1" colspan="1">versus LP</td><td rowspan="1" colspan="1">versus 3.700</td><td rowspan="1" colspan="1">161/388/41 (9.145e&#x02212;05)</td></tr></tbody></table><table-wrap-foot><fn><p>This table reports the average rank of the target class out of the 20 classes, and the pairwise &#x02018;win/draw/loss&#x02019; comparisons of each leave-one-out case between R-NMTF and the baselines, SVMs with linear and rbf kernels, NMTF and LP. The last column reports the statistical significance of the ranking results using Wilcoxon rank sum test.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="gks615-T3" position="float"><label>Table 3.</label><caption><p>Disease phenotype classification results by disease classes</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Disease classes (No)</th><th colspan="5" align="center" rowspan="1">Avg. rank<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">R-NMTF</th><th rowspan="1" colspan="1">NMTF</th><th rowspan="1" colspan="1">SVM- linear</th><th rowspan="1" colspan="1">SVM-rbf</th><th rowspan="1" colspan="1">LP</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Bone (23)</td><td rowspan="1" colspan="1"><bold>3.3</bold></td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">4.7</td><td rowspan="1" colspan="1">7.6</td><td rowspan="1" colspan="1">4.7</td></tr><tr><td rowspan="1" colspan="1">Cancer (53)</td><td rowspan="1" colspan="1"><bold>1.6</bold></td><td rowspan="1" colspan="1">5.0</td><td rowspan="1" colspan="1">4.2</td><td rowspan="1" colspan="1">2.0</td><td rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="1" colspan="1">Cardiovascular (28)</td><td rowspan="1" colspan="1"><bold>3.8</bold></td><td rowspan="1" colspan="1">10.1</td><td rowspan="1" colspan="1">10.0</td><td rowspan="1" colspan="1">6.0</td><td rowspan="1" colspan="1">4.3</td></tr><tr><td rowspan="1" colspan="1">Connective tissue (16)</td><td rowspan="1" colspan="1"><bold>8.5</bold></td><td rowspan="1" colspan="1">8.9</td><td rowspan="1" colspan="1">10.6</td><td rowspan="1" colspan="1">11.4</td><td rowspan="1" colspan="1">11.1</td></tr><tr><td rowspan="1" colspan="1">Dermatological (32)</td><td rowspan="1" colspan="1"><bold>2.0</bold></td><td rowspan="1" colspan="1">4.4</td><td rowspan="1" colspan="1">3.0</td><td rowspan="1" colspan="1">4.0</td><td rowspan="1" colspan="1">2.5</td></tr><tr><td rowspan="1" colspan="1">Developmental (28)</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1"><bold>2.5</bold></td><td rowspan="1" colspan="1">9.6</td><td rowspan="1" colspan="1">9.2</td><td rowspan="1" colspan="1">6.5</td></tr><tr><td rowspan="1" colspan="1">Ear,Nose,Throat (3)</td><td rowspan="1" colspan="1">20.0</td><td rowspan="1" colspan="1">20.0</td><td rowspan="1" colspan="1"><bold>14.7</bold></td><td rowspan="1" colspan="1">15.0</td><td rowspan="1" colspan="1">16.7</td></tr><tr><td rowspan="1" colspan="1">Endocrine (30)</td><td rowspan="1" colspan="1"><bold>4.2</bold></td><td rowspan="1" colspan="1">5.4</td><td rowspan="1" colspan="1">13.4</td><td rowspan="1" colspan="1">5.4</td><td rowspan="1" colspan="1">4.9</td></tr><tr><td rowspan="1" colspan="1">Gastrointestinal (12)</td><td rowspan="1" colspan="1">9.7</td><td rowspan="1" colspan="1">7.8</td><td rowspan="1" colspan="1"><bold>7.8</bold></td><td rowspan="1" colspan="1">9.7</td><td rowspan="1" colspan="1">11.7</td></tr><tr><td rowspan="1" colspan="1">Hematological (30)</td><td rowspan="1" colspan="1">3.5</td><td rowspan="1" colspan="1">9.5</td><td rowspan="1" colspan="1"><bold>2.3</bold></td><td rowspan="1" colspan="1">6.9</td><td rowspan="1" colspan="1">3.8</td></tr><tr><td rowspan="1" colspan="1">Immunological (31)</td><td rowspan="1" colspan="1"><bold>2.6</bold></td><td rowspan="1" colspan="1">10.0</td><td rowspan="1" colspan="1">8.1</td><td rowspan="1" colspan="1">5.2</td><td rowspan="1" colspan="1">2.8</td></tr><tr><td rowspan="1" colspan="1">Metabolic (84)</td><td rowspan="1" colspan="1"><bold>1.0</bold></td><td rowspan="1" colspan="1">2.2</td><td rowspan="1" colspan="1">4.1</td><td rowspan="1" colspan="1">2.2</td><td rowspan="1" colspan="1"><bold>1.0</bold></td></tr><tr><td rowspan="1" colspan="1">Muscular (18)</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1"><bold>5.3</bold></td><td rowspan="1" colspan="1">12.2</td><td rowspan="1" colspan="1">9.1</td><td rowspan="1" colspan="1">7. 3</td></tr><tr><td rowspan="1" colspan="1">Neurological (80)</td><td rowspan="1" colspan="1"><bold>1.4</bold></td><td rowspan="1" colspan="1">6.2</td><td rowspan="1" colspan="1">5.8</td><td rowspan="1" colspan="1">2.7</td><td rowspan="1" colspan="1">1.4</td></tr><tr><td rowspan="1" colspan="1">Nutritional (2)</td><td rowspan="1" colspan="1">16.0</td><td rowspan="1" colspan="1">3.0</td><td rowspan="1" colspan="1">19.0</td><td rowspan="1" colspan="1"><bold>2.0</bold></td><td rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1">Ophthamological (35)</td><td rowspan="1" colspan="1"><bold>1.9</bold></td><td rowspan="1" colspan="1">4.2</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">2.9</td><td rowspan="1" colspan="1">2.5</td></tr><tr><td rowspan="1" colspan="1">Psychiatric (9)</td><td rowspan="1" colspan="1">7.9</td><td rowspan="1" colspan="1"><bold>6.1</bold></td><td rowspan="1" colspan="1">8.0</td><td rowspan="1" colspan="1">11.4</td><td rowspan="1" colspan="1">14.8</td></tr><tr><td rowspan="1" colspan="1">Renal (23)</td><td rowspan="1" colspan="1">4.1</td><td rowspan="1" colspan="1"><bold>3.5</bold></td><td rowspan="1" colspan="1">4.4</td><td rowspan="1" colspan="1">6.8</td><td rowspan="1" colspan="1">4.9</td></tr><tr><td rowspan="1" colspan="1">Respiratory (7)</td><td rowspan="1" colspan="1">15.4</td><td rowspan="1" colspan="1"><bold>10.4</bold></td><td rowspan="1" colspan="1"><bold>10.4</bold></td><td rowspan="1" colspan="1">14.1</td><td rowspan="1" colspan="1">15.7</td></tr><tr><td rowspan="1" colspan="1">Skeletal (46)</td><td rowspan="1" colspan="1"><bold>1.5</bold></td><td rowspan="1" colspan="1">3.3</td><td rowspan="1" colspan="1">4.8</td><td rowspan="1" colspan="1">5.2</td><td rowspan="1" colspan="1">1.8</td></tr></tbody></table><table-wrap-foot><fn><p>This table reports the ranking performance by R-NMTF, SVM with linear and rbf kernels, NMTF and LP in each disease class in the leave-one-out cross-validation. The number of phenotypes in each disease class is reported in the parentheses.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>Performance of disease gene discovery in leave-one-out cross-validation</title><p>In the experiment of disease gene discovery, we collected the member genes in the 200 pathways from KEGG. In the preprocessed data, there are 590 member genes in 27 KEGG disease pathways such as Alzheimer, diabetes and cancer-related pathways. In the leave-one-out cross-validation, each of the 590 member gene was held out and then classified into the 200 pathways as a multi-label classification problem since some of the disease genes are members of multiple pathways. The higher the target pathways in the ranking of the 200 pathways, the better the performance. We measured the performance by the AUC. LP was applied on the PPI network to predict the disease genes as the baseline. The other 589 member genes was used as the initialization of label propagations to classify the held-out gene. The average AUC across the 590 member genes by all the methods are reported in <xref ref-type="table" rid="gks615-T4">Table 4</xref> and <xref ref-type="fig" rid="gks615-F3">Figure 3</xref>. The results clearly show that by integration of phenotype similarity, phenotype class annotation and phenotype&#x02013;gene associations with PPI network R-NMTF more accurately classified the disease genes compared with LP, which only uses the PPI network for disease gene discovery. R-NMTF performed better on &#x0003e;500 cases with an average AUC 0.930 compared with 0.73 by LP.<fig id="gks615-F3" position="float"><label>Figure 3.</label><caption><p>Performance of disease gene discovery in leave-one-out cross-validation. In the plot, the <italic>x</italic>-axis represents AUC cutoffs. The <italic>y</italic>-axis represents the faction of disease genes with a AUC score above the cutoffs. For example, R-NMTF achieved AUCs above 0.9 for &#x0003e;80% of the genes, while LP only achieved the same level of AUC for 20% of the genes.</p></caption><graphic xlink:href="gks615f3p"/></fig>
<table-wrap id="gks615-T4" position="float"><label>Table 4.</label><caption><p>Performance of disease gene discovery in leave-one-out cross-validation</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Compared methods</th><th rowspan="1" colspan="1">Avg. AUC</th><th rowspan="1" colspan="1">win/draw/loss (<italic>P</italic>-value)</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">R-NMTF versus LP</td><td rowspan="1" colspan="1"><bold>0.930</bold> versus 0.730</td><td rowspan="1" colspan="1">526/1/63 (5.4482e&#x02212;113)</td></tr></tbody></table><table-wrap-foot><fn><p>This table reports the average AUC for disease gene classification, and the pairwise &#x02018;win/draw/loss&#x02019; comparisons of each leave-one-out case between R-NMTF and LP. The last column reports the statistical significance of ranking results using Wilcoxon rank sum test.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>Analysis of phenotype clusters with HPO</title><p>To bette characterize the discovered phenotype clusters for the 824 unannotated disease phenotypes, we compared the phenotype clusters with HPO (<xref ref-type="bibr" rid="gks615-B43">43</xref>). HPO describes human phenomic abnormalities with a controlled hierarchical vocabulary. Since the vocabulary in the HPO was developed independently of the disease classification by (<xref ref-type="bibr" rid="gks615-B25">25</xref>), it is an external resources for the validation of the phenotype clusters discovered by R-NMTF. Each OMIM phenotype was mapped to the hierarchy of HPO to retrieve the matched HPO terms. Then, a new HPO similarity is calculated for each pair of phenotypes by Jaccard similarity coefficient
<disp-formula><graphic xlink:href="gks615u12"/></disp-formula>
where <italic>P</italic><sub>1</sub> and <italic>P</italic><sub>2</sub> are the set of the matched HPO terms of the two phenotypes, respectively. We arranged the phenotypes into the 20 disease classes (clusters) based on the R-NMTF clustering, and show their HPO similarity by a heat map in <xref ref-type="fig" rid="gks615-F4">Figure 4</xref>. There are clearly block structures among the predicted 20 clusters. Most of the phenotypes in the same cluster also share strong HPO similarity. The consistency between the predicted disease clusters and HPO similarities suggest that R-NMTF produced a phenotype clustering supported by HPO annotations. Another interesting observation is that there are also strong HPO similarities between different clusters (i.e. different disease classes share HPO similarities). This may imply that some of the disease classes may share common molecular mechanisms such as skeletal diseases and developmental diseases.<fig id="gks615-F4" position="float"><label>Figure 4.</label><caption><p>HPO phenotype similarities by clusters. The HPO similarity matrix of the phenotypes are display as a heap map. The phenotypes are grouped into 20 clusters with the disease classes annotated below.</p></caption><graphic xlink:href="gks615f4p"/></fig></p></sec><sec><title>Analysis of new phenotypes in disease classes</title><p><xref ref-type="table" rid="gks615-T5">Table 5</xref> lists the newly predicted disease phenotypes in the 20 disease classes. Our survey identified supporting literatures for many of the predictions. One interesting finding is faconi anemia (FA) (OMIM:227650), a rare, inherited blood disorder, predicted as a cancer-related disease. Surprisingly, a recent study found that FA could share a common pathogenesis with diseases related with chromosomal instability including cancers, and suggested a possible use of cancer treatment for patients with FA (<xref ref-type="bibr" rid="gks615-B48">48</xref>). R-NMTF also predicted Proteus syndrome (OMIM:176920) as a cancer-related disease. PTEN, a well-known tumor suppressor gene, is a known causative gene for Proteus syndrome, which may indicate that cancer risk accompanying Proteus syndrome could be increased (<xref ref-type="bibr" rid="gks615-B49 gks615-B50 gks615-B51 gks615-B52">49&#x02013;52</xref>). Other interesting newly predicted disease phenotypes are Amyotrophic lateral sclerosis (ALS) (OMIM:105400), also known as Lou Gehrig's disease in neurological disease class, and Gambling, pathologic (OMIM:606349) in psychiatric disease class. ALS is a disease of the nerve cells in the brain and causes unstable muscle movement and Gambling, pathologic is a disabling disorder to fail to resist impulses to gamble, known for frequently co-occur with other psychiatric disorders (<xref ref-type="bibr" rid="gks615-B85">85</xref>,<xref ref-type="bibr" rid="gks615-B86">86</xref>). R-NMTF also accurately predicted a few disease phenotypes including juvenile myelomonocytic leukemia and breast cancer which were previously missed in the annotation of the cancer disease class (<xref ref-type="bibr" rid="gks615-B25">25</xref>). These findings suggest that R-NMTF could correctly classify complex and rare disease phenotypes into their relevant disease classes, which could be used to guide clinical decisions.
<table-wrap id="gks615-T5" position="float"><label>Table 5.</label><caption><p>New disease phenotypes in 20 disease classes</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Disease classes</th><th colspan="5" align="center" rowspan="1">New disease phenotypes</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Bone</td><td rowspan="1" colspan="1">Achondrogenesis, Type III (<xref ref-type="bibr" rid="gks615-B44">44</xref>)</td><td rowspan="1" colspan="1">Canine Teeth (Omim:114600)</td><td rowspan="1" colspan="1">Dens Evaginatus (<xref ref-type="bibr" rid="gks615-B45">45</xref>)</td><td rowspan="1" colspan="1">Dental Noneruption (<xref ref-type="bibr" rid="gks615-B46">46</xref>)</td><td rowspan="1" colspan="1">Dentin Dysplasia, Type I(<xref ref-type="bibr" rid="gks615-B47">47</xref>)</td></tr><tr><td rowspan="1" colspan="1">Cancer</td><td rowspan="1" colspan="1">Fanconi Anemia (<xref ref-type="bibr" rid="gks615-B48">48</xref>)</td><td rowspan="1" colspan="1">Juvenile Myelomonocytic Leukemia</td><td rowspan="1" colspan="1">Breast Cancer</td><td rowspan="1" colspan="1">Proteus Syndrome (<xref ref-type="bibr" rid="gks615-B49">49</xref>,<xref ref-type="bibr" rid="gks615-B50">50</xref>,<xref ref-type="bibr" rid="gks615-B51">51</xref>,<xref ref-type="bibr" rid="gks615-B52">52</xref>)</td><td rowspan="1" colspan="1">Bannayan-Riley-Ruvalcaba Syndrome (<xref ref-type="bibr" rid="gks615-B53">53</xref>,<xref ref-type="bibr" rid="gks615-B54">54</xref>)</td></tr><tr><td rowspan="1" colspan="1">Cardiovascular</td><td rowspan="1" colspan="1">Cardiomyopathy (Omim:192600)</td><td rowspan="1" colspan="1">Atrial Standstill (<xref ref-type="bibr" rid="gks615-B55">55</xref>)</td><td rowspan="1" colspan="1">Cardiomyopathy, Dilated, 1E</td><td rowspan="1" colspan="1">Long Qt Syndrome 3 (<xref ref-type="bibr" rid="gks615-B56">56</xref>,<xref ref-type="bibr" rid="gks615-B57">57</xref>)</td><td rowspan="1" colspan="1">Sudden Infant Death Syndrome (<xref ref-type="bibr" rid="gks615-B58">58</xref>)</td></tr><tr><td rowspan="1" colspan="1">Connective tissue</td><td rowspan="1" colspan="1">Arthritis, Sacroiliac (<xref ref-type="bibr" rid="gks615-B59">59</xref>)</td><td rowspan="1" colspan="1">Spondyloarthropathy (Omim:183840)</td><td rowspan="1" colspan="1">Slipped Femoral Capital Epiphyses (<xref ref-type="bibr" rid="gks615-B60">60</xref>)</td><td rowspan="1" colspan="1">Facial Asymmetry (<xref ref-type="bibr" rid="gks615-B61">61</xref>)</td><td rowspan="1" colspan="1">Cervical Rib</td></tr><tr><td rowspan="1" colspan="1">Dermatological</td><td rowspan="1" colspan="1">Deafness; Dfna3 (<xref ref-type="bibr" rid="gks615-B62">62</xref>)</td><td rowspan="1" colspan="1">Epidermolysis Bullosa (Omim:131800)</td><td rowspan="1" colspan="1">Pachyonychia Congenita, Type 1 (<xref ref-type="bibr" rid="gks615-B63">63</xref>)</td><td rowspan="1" colspan="1">Epidermolysis Bullosa Herpetiformis (<xref ref-type="bibr" rid="gks615-B64">64</xref>)</td><td rowspan="1" colspan="1">Epidermolysis Bullosa Simplex, Koebner Type (<xref ref-type="bibr" rid="gks615-B64">64</xref>)</td></tr><tr><td rowspan="1" colspan="1">Developmental</td><td rowspan="1" colspan="1">Leucine Transport, High</td><td rowspan="1" colspan="1">Uterine Anomalies (<xref ref-type="bibr" rid="gks615-B65">65</xref>)</td><td rowspan="1" colspan="1">Testes, Rudimentary (<xref ref-type="bibr" rid="gks615-B66">66</xref>)</td><td rowspan="1" colspan="1">Oligosynaptic Infertility</td><td rowspan="1" colspan="1">Hypospadias, Autosomal (<xref ref-type="bibr" rid="gks615-B67">67</xref>)</td></tr><tr><td rowspan="1" colspan="1">Ear,Nose,Throat</td><td rowspan="1" colspan="1">Otosclerosis 3 (<xref ref-type="bibr" rid="gks615-B68">68</xref>)</td><td rowspan="1" colspan="1">Otosclerosis 2 (<xref ref-type="bibr" rid="gks615-B68">68</xref>)</td><td rowspan="1" colspan="1">Otosclerosis 5 (<xref ref-type="bibr" rid="gks615-B68">68</xref>)</td><td rowspan="1" colspan="1">Periodontitis, Aggressive, 2</td><td rowspan="1" colspan="1">Red Cell Permeability Defect</td></tr><tr><td rowspan="1" colspan="1">Endocrine</td><td rowspan="1" colspan="1">Diabetes Mellitus</td><td rowspan="1" colspan="1">Hypoglycemia (Omim:601820) (<xref ref-type="bibr" rid="gks615-B69">69</xref>)</td><td rowspan="1" colspan="1">Polycystic Ovary Syndrome 1 (<xref ref-type="bibr" rid="gks615-B70">70</xref>)</td><td rowspan="1" colspan="1">Diabetes Mellitus, Transient Neonatal</td><td rowspan="1" colspan="1">Goiter, Multinodular 2 (<xref ref-type="bibr" rid="gks615-B71">71</xref>)</td></tr><tr><td rowspan="1" colspan="1">Gastrointestinal</td><td rowspan="1" colspan="1">Cholestasis2 (Omim:605479) (<xref ref-type="bibr" rid="gks615-B72">72</xref>)</td><td rowspan="1" colspan="1">Bile Acid, Synthetic Defect Of</td><td rowspan="1" colspan="1">Cholestasis; Pfic2 (Omim:601847) (<xref ref-type="bibr" rid="gks615-B72">72</xref>)</td><td rowspan="1" colspan="1">Cholestasis; Pfic3 (Omim:602347) (<xref ref-type="bibr" rid="gks615-B72">72</xref>)</td><td rowspan="1" colspan="1">Pancreatitis, Hereditary (<xref ref-type="bibr" rid="gks615-B73">73</xref>)</td></tr><tr><td rowspan="1" colspan="1">Hematological</td><td rowspan="1" colspan="1">Anemia (<xref ref-type="bibr" rid="gks615-B74">74</xref>)</td><td rowspan="1" colspan="1">Hyperheparinemia</td><td rowspan="1" colspan="1">Sideroblastic Anemia, Autosomal (<xref ref-type="bibr" rid="gks615-B75">75</xref>)</td><td rowspan="1" colspan="1">Platelet Groups&#x02013;ko System</td><td rowspan="1" colspan="1">Anemia, Familial Pyridoxine-Responsive (<xref ref-type="bibr" rid="gks615-B76">76</xref>)</td></tr><tr><td rowspan="1" colspan="1">Immunological</td><td rowspan="1" colspan="1">Herpesvirus Sensitivity (<xref ref-type="bibr" rid="gks615-B77">77</xref>)</td><td rowspan="1" colspan="1">Interleukin (Omim:243110) (<xref ref-type="bibr" rid="gks615-B78">78</xref>)</td><td rowspan="1" colspan="1">Panbronchiolitis, Diffuse (<xref ref-type="bibr" rid="gks615-B79">79</xref>)</td><td rowspan="1" colspan="1">Immune Deficiency Disease</td><td rowspan="1" colspan="1">Allergic Bronchopulmonary Aspergillosis (<xref ref-type="bibr" rid="gks615-B80">80</xref>)</td></tr><tr><td rowspan="1" colspan="1">Metabolic</td><td rowspan="1" colspan="1">Immunoglobulin D Level In Plasma</td><td rowspan="1" colspan="1">Magnesium, Elevated Red Cell</td><td rowspan="1" colspan="1">Flood Factor Deficiency</td><td rowspan="1" colspan="1">Citrulline Transport Defect</td><td rowspan="1" colspan="1">Amobarbital, Deficient N-Hydroxylation of</td></tr><tr><td rowspan="1" colspan="1">Muscular</td><td rowspan="1" colspan="1">Palmomental Reflex</td><td rowspan="1" colspan="1">Myopathy (Omim:255100)</td><td rowspan="1" colspan="1">Muscular Hypoplasia</td><td rowspan="1" colspan="1">Pleoconial Myopathy With Salt Craving</td><td rowspan="1" colspan="1">Myopathy, Congenital</td></tr><tr><td rowspan="1" colspan="1">Neurological</td><td rowspan="1" colspan="1">Amyotrophic Lateral Sclerosis 1</td><td rowspan="1" colspan="1">Amyotrophic Lateral Sclerosis 2</td><td rowspan="1" colspan="1">Alzheimer Disease 2</td><td rowspan="1" colspan="1">Prion Disease (Omim:603218)</td><td rowspan="1" colspan="1">Frontotemporal Dementia (Omim:607485)</td></tr><tr><td rowspan="1" colspan="1">Nutritional</td><td rowspan="1" colspan="1">Bulimia Nervosa</td><td rowspan="1" colspan="1">Red Cell Permeability Defect</td><td rowspan="1" colspan="1">Labia Minora (Omim:149600) (<xref ref-type="bibr" rid="gks615-B81">81</xref>)</td><td rowspan="1" colspan="1">Schizophrenia 9 (<xref ref-type="bibr" rid="gks615-B82">82</xref>)</td><td rowspan="1" colspan="1">Amyotrophic Lateral Sclerosis 6 (<xref ref-type="bibr" rid="gks615-B83">83</xref>)</td></tr><tr><td rowspan="1" colspan="1">Ophthamological</td><td rowspan="1" colspan="1">Cone Dystrophy 3</td><td rowspan="1" colspan="1">Cone-Rod Dystrophy 3</td><td rowspan="1" colspan="1">Leber Congenital Amaurosis</td><td rowspan="1" colspan="1">Cone-Rod Dystrophy 6</td><td rowspan="1" colspan="1">Retinitis Pigmentosa 19</td></tr><tr><td rowspan="1" colspan="1">Psychiatric</td><td rowspan="1" colspan="1">Fg Syndrome 2 (<xref ref-type="bibr" rid="gks615-B86">86</xref>)</td><td rowspan="1" colspan="1">Fg Syndrome 3 (<xref ref-type="bibr" rid="gks615-B84">84</xref>)</td><td rowspan="1" colspan="1">Schizophrenia 5</td><td rowspan="1" colspan="1">Cerebral Angiopathy, Dysphoric (<xref ref-type="bibr" rid="gks615-B85">85</xref>,<xref ref-type="bibr" rid="gks615-B86">86</xref>)</td><td rowspan="1" colspan="1">Gambling, Pathologic</td></tr><tr><td rowspan="1" colspan="1">Renal</td><td rowspan="1" colspan="1">Nephrotic Syndrome, Type 2 (<xref ref-type="bibr" rid="gks615-B87">87</xref>,<xref ref-type="bibr" rid="gks615-B88">88</xref>)</td><td rowspan="1" colspan="1">Hypertensive Nephropathy (<xref ref-type="bibr" rid="gks615-B89">89</xref>)</td><td rowspan="1" colspan="1">Enuresis, Nocturnal, 2 (<xref ref-type="bibr" rid="gks615-B90">90</xref>)</td><td rowspan="1" colspan="1">Enuresis, Nocturnal, 1 (<xref ref-type="bibr" rid="gks615-B90">90</xref>)</td><td rowspan="1" colspan="1">Blue Diaper Syndrome</td></tr><tr><td rowspan="1" colspan="1">Respiratory</td><td rowspan="1" colspan="1">Hemangiomatosis</td><td rowspan="1" colspan="1">Respiratory Underresponsiveness</td><td rowspan="1" colspan="1">Emphysema (Omim:130700)</td><td rowspan="1" colspan="1">Asthma, Short Stature, and Elevated Iga</td><td rowspan="1" colspan="1">Asthma-Related Traits, Susceptibility To, 1</td></tr><tr><td rowspan="1" colspan="1">Skeletal</td><td rowspan="1" colspan="1">Brachydactyly, Mononen Type</td><td rowspan="1" colspan="1">Tibial Hemimelia (<xref ref-type="bibr" rid="gks615-B91">91</xref>)</td><td rowspan="1" colspan="1">Acropectoral Syndrome</td><td rowspan="1" colspan="1">Syndactyly, Type IV</td><td rowspan="1" colspan="1">Spondyloepimetaphyseal Dysplasia, Irapa Type</td></tr></tbody></table><table-wrap-foot><fn><p>The 5 most confident predictions of phenotypes in each disease class are reported.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>Analysis of new member genes in disease pathways</title><p>KEGG provides a list of manually curated disease pathways. However, the current knowledge of biological pathways related with diseases is still incomplete and inaccurate, and there are many missing member genes in the disease-related pathways. <xref ref-type="table" rid="gks615-T6">Table 6</xref> lists the newly predicted member genes in the KEGG disease pathways. Our literature review also identified supporting evidences for many of the predictions. Interesting examples include TMED10 and PRND, which are newly predicted member genes in Alzheimer's pathway and Prion disease pathway, respectively. TMED10 inhibits production of amyloid beta peptides, which is a critical feature of Alzheimers disease and RPND (prion protein 2) is known for that mutations in this gene may lead to neurological disorders. Other examples include EXO1 and ADIPOR1 in colorectal cancer pathway and FGFR3 and FGFR4 in melanoma pathway. Single nucleotide polymorphisms in EXO1 increases risk of colorectal cancer (<xref ref-type="bibr" rid="gks615-B106">106</xref>,<xref ref-type="bibr" rid="gks615-B107">107</xref>), and expression of ADIPOR1 is known for involving cancer progression in colorectal cancer (<xref ref-type="bibr" rid="gks615-B108">108</xref>,<xref ref-type="bibr" rid="gks615-B109">109</xref>). Mutations in FGFR3 and FGFR4 were previously described in melanoma (<xref ref-type="bibr" rid="gks615-B121">121</xref>).
<table-wrap id="gks615-T6" position="float"><label>Table 6.</label><caption><p>New member genes of KEGG disease pathways</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Kegg disease pathways</th><th colspan="10" align="center" rowspan="1">New member genes</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Hsa04930: Type II Diabetes Mellitus</td><td rowspan="1" colspan="1">KCNJ8 (<xref ref-type="bibr" rid="gks615-B92">92</xref>)</td><td rowspan="1" colspan="1">EFHC1</td><td rowspan="1" colspan="1">ADIPOR2 (<xref ref-type="bibr" rid="gks615-B93">93</xref>)</td><td rowspan="1" colspan="1">ABCC9</td><td rowspan="1" colspan="1">LDHA</td><td rowspan="1" colspan="1">CDH13 (<xref ref-type="bibr" rid="gks615-B94">94</xref>)</td><td rowspan="1" colspan="1">ENSA</td><td rowspan="1" colspan="1">CRYBB1</td><td rowspan="1" colspan="1">CASR</td><td rowspan="1" colspan="1">KCNJ2</td></tr><tr><td rowspan="1" colspan="1">Hsa04940: Type I Diabetes Mellitus</td><td rowspan="1" colspan="1">CKAP5</td><td rowspan="1" colspan="1">SPTBN4</td><td rowspan="1" colspan="1">PTPRT</td><td rowspan="1" colspan="1">SNX19</td><td rowspan="1" colspan="1">CD74</td><td rowspan="1" colspan="1">LILRB1 (<xref ref-type="bibr" rid="gks615-B95">95</xref>)</td><td rowspan="1" colspan="1">LILRB2</td><td rowspan="1" colspan="1">GAST</td><td rowspan="1" colspan="1">LRRC23</td><td rowspan="1" colspan="1">CTLA4 (<xref ref-type="bibr" rid="gks615-B96">96</xref>)</td></tr><tr><td rowspan="1" colspan="1">Hsa04950: Maturity Onset Diabetes of the Young</td><td rowspan="1" colspan="1">OLIG2</td><td rowspan="1" colspan="1">EN2</td><td rowspan="1" colspan="1">PCSK1</td><td rowspan="1" colspan="1">PNRC1</td><td rowspan="1" colspan="1">PCSK2</td><td rowspan="1" colspan="1">GATA5</td><td rowspan="1" colspan="1">GATA6</td><td rowspan="1" colspan="1">PNRC2</td><td rowspan="1" colspan="1">OTX2</td><td rowspan="1" colspan="1">RAMP2</td></tr><tr><td rowspan="1" colspan="1">Hsa05010: Alzheimers Disease</td><td rowspan="1" colspan="1">TMED10 (<xref ref-type="bibr" rid="gks615-B97">97</xref>)</td><td rowspan="1" colspan="1">BRI3</td><td rowspan="1" colspan="1">PTX3</td><td rowspan="1" colspan="1">APH1B (<xref ref-type="bibr" rid="gks615-B98">98</xref>)</td><td rowspan="1" colspan="1">TFCP2 (<xref ref-type="bibr" rid="gks615-B99">99</xref>)</td><td rowspan="1" colspan="1">HRG</td><td rowspan="1" colspan="1">C1R</td><td rowspan="1" colspan="1">FKBP2</td><td rowspan="1" colspan="1">KHSRP</td><td rowspan="1" colspan="1">NEDD8 (<xref ref-type="bibr" rid="gks615-B100">100</xref>)</td></tr><tr><td rowspan="1" colspan="1">Hsa05020: Parkinsons Disease</td><td rowspan="1" colspan="1">ARIH1 (<xref ref-type="bibr" rid="gks615-B101">101</xref>)</td><td rowspan="1" colspan="1">AMFR</td><td rowspan="1" colspan="1">AGXT</td><td rowspan="1" colspan="1">TRIM25</td><td rowspan="1" colspan="1">CCNB1IP1</td><td rowspan="1" colspan="1">GAN</td><td rowspan="1" colspan="1">TMCC2</td><td rowspan="1" colspan="1">STUB1</td><td rowspan="1" colspan="1">SH2D3C</td><td rowspan="1" colspan="1">SLC6A1</td></tr><tr><td rowspan="1" colspan="1">Hsa05030: ALS</td><td rowspan="1" colspan="1">SSR3</td><td rowspan="1" colspan="1">JUB</td><td rowspan="1" colspan="1">ALS2CL (<xref ref-type="bibr" rid="gks615-B102">102</xref>)</td><td rowspan="1" colspan="1">APBA1</td><td rowspan="1" colspan="1">MTMR2</td><td rowspan="1" colspan="1">ABL2</td><td rowspan="1" colspan="1">HOXB2</td><td rowspan="1" colspan="1">RAB37</td><td rowspan="1" colspan="1">PKN1 (<xref ref-type="bibr" rid="gks615-B103">103</xref>)</td><td rowspan="1" colspan="1">CHML</td></tr><tr><td rowspan="1" colspan="1">Hsa05040: Huntingtons Disease</td><td rowspan="1" colspan="1">HIP1R (<xref ref-type="bibr" rid="gks615-B104">104</xref>)</td><td rowspan="1" colspan="1">SNX5</td><td rowspan="1" colspan="1">IFT20</td><td rowspan="1" colspan="1">PICALM</td><td rowspan="1" colspan="1">RPS10</td><td rowspan="1" colspan="1">PQBP1</td><td rowspan="1" colspan="1">NECAP1</td><td rowspan="1" colspan="1">ARF1</td><td rowspan="1" colspan="1">KPNA4</td><td rowspan="1" colspan="1">MBTPS1</td></tr><tr><td rowspan="1" colspan="1">Hsa05050: Dentatorubropallidoluysian Atrophy</td><td rowspan="1" colspan="1">ALG13</td><td rowspan="1" colspan="1">TRIM22</td><td rowspan="1" colspan="1">CLCN5</td><td rowspan="1" colspan="1">ECM1</td><td rowspan="1" colspan="1">MYST3</td><td rowspan="1" colspan="1">NET1</td><td rowspan="1" colspan="1">SYNPO</td><td rowspan="1" colspan="1">EFEMP1</td><td rowspan="1" colspan="1">CPSF6</td><td rowspan="1" colspan="1">NDFIP2</td></tr><tr><td rowspan="1" colspan="1">Hsa05060: Prion Disease</td><td rowspan="1" colspan="1">PRND (<xref ref-type="bibr" rid="gks615-B106">106</xref>)</td><td rowspan="1" colspan="1">CHD6</td><td rowspan="1" colspan="1">LAMA2</td><td rowspan="1" colspan="1">RPS21</td><td rowspan="1" colspan="1">EIF2AK3</td><td rowspan="1" colspan="1">KEAP1</td><td rowspan="1" colspan="1">ADAM23</td><td rowspan="1" colspan="1">DPP6</td><td rowspan="1" colspan="1">MOG</td><td rowspan="1" colspan="1">OPCML</td></tr><tr><td rowspan="1" colspan="1">Hsa05110: Cholera Infection</td><td rowspan="1" colspan="1">SERP1</td><td rowspan="1" colspan="1">SEC63</td><td rowspan="1" colspan="1">ARFIP2</td><td rowspan="1" colspan="1">APOB</td><td rowspan="1" colspan="1">ARFIP1</td><td rowspan="1" colspan="1">PIP5K1A</td><td rowspan="1" colspan="1">FLAD1</td><td rowspan="1" colspan="1">TRAM1</td><td rowspan="1" colspan="1">ETHE1</td><td rowspan="1" colspan="1">AP1B1</td></tr><tr><td rowspan="1" colspan="1">Hsa05120: Epithelial Cell Signaling in Helicobacter Pylori Infection</td><td rowspan="1" colspan="1">GRLF1</td><td rowspan="1" colspan="1">ETHE1</td><td rowspan="1" colspan="1">HBA1</td><td rowspan="1" colspan="1">EFNA2</td><td rowspan="1" colspan="1">TOMM34</td><td rowspan="1" colspan="1">DARC</td><td rowspan="1" colspan="1">ADD2</td><td rowspan="1" colspan="1">SH3D19</td><td rowspan="1" colspan="1">PFKM</td><td rowspan="1" colspan="1">ANG</td></tr><tr><td rowspan="1" colspan="1">Hsa05130: Pathogenic Escherichia Coli Infection Ehec</td><td rowspan="1" colspan="1">ARPC4</td><td rowspan="1" colspan="1">GRM7</td><td rowspan="1" colspan="1">HS1BP3</td><td rowspan="1" colspan="1">CGN</td><td rowspan="1" colspan="1">PLA2G7</td><td rowspan="1" colspan="1">KIAA1543</td><td rowspan="1" colspan="1">LAPTM4A</td><td rowspan="1" colspan="1">NOX4</td><td rowspan="1" colspan="1">ACTR2</td><td rowspan="1" colspan="1">SSB</td></tr><tr><td rowspan="1" colspan="1">Hsa05210: Colorectal Cancer</td><td rowspan="1" colspan="1">EXO1 (<xref ref-type="bibr" rid="gks615-B106">106</xref>,<xref ref-type="bibr" rid="gks615-B107">107</xref>)</td><td rowspan="1" colspan="1">ADIPOR1 (<xref ref-type="bibr" rid="gks615-B108">108</xref>,<xref ref-type="bibr" rid="gks615-B109">109</xref>)</td><td rowspan="1" colspan="1">MUTYH (<xref ref-type="bibr" rid="gks615-B111">111</xref>)</td><td rowspan="1" colspan="1">PMS2</td><td rowspan="1" colspan="1">CDCA8</td><td rowspan="1" colspan="1">ROR2</td><td rowspan="1" colspan="1">PMS1</td><td rowspan="1" colspan="1">MAZ</td><td rowspan="1" colspan="1">WNT5A</td><td rowspan="1" colspan="1">WNT7A</td></tr><tr><td rowspan="1" colspan="1">Hsa05211: Renal Cell Carcinoma</td><td rowspan="1" colspan="1">HIF3A</td><td rowspan="1" colspan="1">OS9</td><td rowspan="1" colspan="1">EGLN2</td><td rowspan="1" colspan="1">ING4</td><td rowspan="1" colspan="1">ARNTL2</td><td rowspan="1" colspan="1">SIM1</td><td rowspan="1" colspan="1">ASB8</td><td rowspan="1" colspan="1">LRRC41</td><td rowspan="1" colspan="1">SENP6</td><td rowspan="1" colspan="1">SIM2</td></tr><tr><td rowspan="1" colspan="1">Hsa05212: Pancreatic Cancer</td><td rowspan="1" colspan="1">REPS1</td><td rowspan="1" colspan="1">REPS2</td><td rowspan="1" colspan="1">PLCD1</td><td rowspan="1" colspan="1">SHFM1</td><td rowspan="1" colspan="1">EXOC1</td><td rowspan="1" colspan="1">RAD51AP1</td><td rowspan="1" colspan="1">RAD54L</td><td rowspan="1" colspan="1">RALGPS1</td><td rowspan="1" colspan="1">EXOC5</td><td rowspan="1" colspan="1">EXOC3</td></tr><tr><td rowspan="1" colspan="1">Hsa05213: Endometrial Cancer</td><td rowspan="1" colspan="1">MSR1</td><td rowspan="1" colspan="1">BRCA2 (<xref ref-type="bibr" rid="gks615-B112">112</xref>)</td><td rowspan="1" colspan="1">NF1</td><td rowspan="1" colspan="1">MXI1 (<xref ref-type="bibr" rid="gks615-B113">113</xref>)</td><td rowspan="1" colspan="1">RNASEL</td><td rowspan="1" colspan="1">FH</td><td rowspan="1" colspan="1">MSH2</td><td rowspan="1" colspan="1">ELAC2</td><td rowspan="1" colspan="1">MAD1L1</td><td rowspan="1" colspan="1">CHEK2</td></tr><tr><td rowspan="1" colspan="1">Hsa05214: Glioma</td><td rowspan="1" colspan="1">PDAP1</td><td rowspan="1" colspan="1">KIAA1683</td><td rowspan="1" colspan="1">RHBDF1</td><td rowspan="1" colspan="1">RPS18</td><td rowspan="1" colspan="1">ART1</td><td rowspan="1" colspan="1">BRD2</td><td rowspan="1" colspan="1">NKD2</td><td rowspan="1" colspan="1">MYO10</td><td rowspan="1" colspan="1">TFDP2</td><td rowspan="1" colspan="1">SETD8</td></tr><tr><td rowspan="1" colspan="1">Hsa05215: Prostate Cancer</td><td rowspan="1" colspan="1">KRT27</td><td rowspan="1" colspan="1">MTTP</td><td rowspan="1" colspan="1">ATF6 (<xref ref-type="bibr" rid="gks615-B114">114</xref>)</td><td rowspan="1" colspan="1">PTHLH (<xref ref-type="bibr" rid="gks615-B115">115</xref>)</td><td rowspan="1" colspan="1">SEMG1</td><td rowspan="1" colspan="1">ATF2 (<xref ref-type="bibr" rid="gks615-B116">116</xref>)</td><td rowspan="1" colspan="1">G6PC</td><td rowspan="1" colspan="1">NFIL3 (<xref ref-type="bibr" rid="gks615-B117">117</xref>)</td><td rowspan="1" colspan="1">ASGR1</td><td rowspan="1" colspan="1">MALL</td></tr><tr><td rowspan="1" colspan="1">Hsa05216: Thyroid Cancer</td><td rowspan="1" colspan="1">TSSK2</td><td rowspan="1" colspan="1">TMOD2</td><td rowspan="1" colspan="1">RNF14</td><td rowspan="1" colspan="1">TRIM25</td><td rowspan="1" colspan="1">PPP4C</td><td rowspan="1" colspan="1">IFI16</td><td rowspan="1" colspan="1">CNN1</td><td rowspan="1" colspan="1">TMOD1</td><td rowspan="1" colspan="1">S100A2</td><td rowspan="1" colspan="1">NUP98</td></tr><tr><td rowspan="1" colspan="1">Hsa05217: Basal Cell Carcinoma</td><td rowspan="1" colspan="1">IHH</td><td rowspan="1" colspan="1">DHH</td><td rowspan="1" colspan="1">ZIC1</td><td rowspan="1" colspan="1">ZIC2</td><td rowspan="1" colspan="1">PORCN</td><td rowspan="1" colspan="1">SFRP1</td><td rowspan="1" colspan="1">ROR2</td><td rowspan="1" colspan="1">FRMPD4</td><td rowspan="1" colspan="1">GPC3</td><td rowspan="1" colspan="1">GAS1</td></tr><tr><td rowspan="1" colspan="1">Hsa05218: Melanoma</td><td rowspan="1" colspan="1">FGFR4 (<xref ref-type="bibr" rid="gks615-B118">118</xref>)</td><td rowspan="1" colspan="1">FGFR2 (<xref ref-type="bibr" rid="gks615-B119">119</xref>)</td><td rowspan="1" colspan="1">PHEX</td><td rowspan="1" colspan="1">FGFR3 (<xref ref-type="bibr" rid="gks615-B120">120</xref>,<xref ref-type="bibr" rid="gks615-B121">121</xref>)</td><td rowspan="1" colspan="1">SCN8A</td><td rowspan="1" colspan="1">EBNA1BP2</td><td rowspan="1" colspan="1">RPS2</td><td rowspan="1" colspan="1">MAPK8IP2</td><td rowspan="1" colspan="1">TFEB</td><td rowspan="1" colspan="1">PDAP1</td></tr><tr><td rowspan="1" colspan="1">Hsa05219: Bladder Cancer</td><td rowspan="1" colspan="1">MLC1</td><td rowspan="1" colspan="1">UNC5B (<xref ref-type="bibr" rid="gks615-B122">122</xref>)</td><td rowspan="1" colspan="1">UNC5A</td><td rowspan="1" colspan="1">PAWR</td><td rowspan="1" colspan="1">AATF</td><td rowspan="1" colspan="1">TNXB</td><td rowspan="1" colspan="1">CAMK2A</td><td rowspan="1" colspan="1">RECK</td><td rowspan="1" colspan="1">HIST3H2A</td><td rowspan="1" colspan="1">ATF4 (<xref ref-type="bibr" rid="gks615-B123">123</xref>)</td></tr><tr><td rowspan="1" colspan="1">Hsa05220: Chronic Myeloid Leukemia</td><td rowspan="1" colspan="1">APBA3</td><td rowspan="1" colspan="1">MAP4K5 (<xref ref-type="bibr" rid="gks615-B124">124</xref>)</td><td rowspan="1" colspan="1">BAZ2B</td><td rowspan="1" colspan="1">KLF3</td><td rowspan="1" colspan="1">TDGF1</td><td rowspan="1" colspan="1">MAPK4</td><td rowspan="1" colspan="1">FMOD</td><td rowspan="1" colspan="1">RAI2</td><td rowspan="1" colspan="1">ELF2</td><td rowspan="1" colspan="1">SPRY2 (<xref ref-type="bibr" rid="gks615-B125">125</xref>)</td></tr><tr><td rowspan="1" colspan="1">Hsa05221 Acute Myeloid Leukemia</td><td rowspan="1" colspan="1">RPL21</td><td rowspan="1" colspan="1">NDUFB8 (<xref ref-type="bibr" rid="gks615-B126">126</xref>)</td><td rowspan="1" colspan="1">FBXO18</td><td rowspan="1" colspan="1">GATA2 (<xref ref-type="bibr" rid="gks615-B127">127</xref>)</td><td rowspan="1" colspan="1">CEBPD (<xref ref-type="bibr" rid="gks615-B128">128</xref>)</td><td rowspan="1" colspan="1">GFI1 (<xref ref-type="bibr" rid="gks615-B129">129</xref>)</td><td rowspan="1" colspan="1">TAF9B</td><td rowspan="1" colspan="1">MYST3 (<xref ref-type="bibr" rid="gks615-B130">130</xref>)</td><td rowspan="1" colspan="1">CBFA2T3</td><td rowspan="1" colspan="1">NFATC1</td></tr><tr><td rowspan="1" colspan="1">Hsa05222: Small Cell Lung Cancer</td><td rowspan="1" colspan="1">CKS2</td><td rowspan="1" colspan="1">BCKDK</td><td rowspan="1" colspan="1">TBC1D8</td><td rowspan="1" colspan="1">TNFRSF19</td><td rowspan="1" colspan="1">DUSP1</td><td rowspan="1" colspan="1">TNFRSF4</td><td rowspan="1" colspan="1">TNFRSF12A</td><td rowspan="1" colspan="1">NGFRAP1</td><td rowspan="1" colspan="1">LTBR</td><td rowspan="1" colspan="1">MAP6</td></tr><tr><td rowspan="1" colspan="1">Hsa05223: Non Small Cell Lung Cancer</td><td rowspan="1" colspan="1">FDXR (<xref ref-type="bibr" rid="gks615-B131">131</xref>)</td><td rowspan="1" colspan="1">LATS1 (<xref ref-type="bibr" rid="gks615-B132">132</xref>)</td><td rowspan="1" colspan="1">MAP6</td><td rowspan="1" colspan="1">NR1H2 (<xref ref-type="bibr" rid="gks615-B133">133</xref>)</td><td rowspan="1" colspan="1">PRKRIR</td><td rowspan="1" colspan="1">CSN1S1</td><td rowspan="1" colspan="1">NR1H3</td><td rowspan="1" colspan="1">CNKSR1</td><td rowspan="1" colspan="1">FOXG1 (<xref ref-type="bibr" rid="gks615-B134">134</xref>)</td><td rowspan="1" colspan="1">PNRC1</td></tr></tbody></table><table-wrap-foot><fn><p>The 10 most confident predictions of member genes in KEGG disease pathways are reported.</p></fn></table-wrap-foot></table-wrap></p><p>We also provide a network view of three examples of disease pathways with addition of the newly predicted member genes in <xref ref-type="fig" rid="gks615-F5">Figure 5</xref>. These examples demonstrate that, while KEGG disease pathways were manually curated, there are still missing member genes in the pathways. One example is WNT5A, a newly predicted member gene in the colorectal cancer pathway in <xref ref-type="fig" rid="gks615-F5">Figure 5</xref>A. Recent study showed that WNT5A is a potential biomarker for colorectal cancer and could act as tumor suppressor for colorectal cancer by antagonizing the WNT signaling pathway (<xref ref-type="bibr" rid="gks615-B135">135</xref>). Another example is FGFR3 gene, the newly predicted member gene in the melanoma pathway, in <xref ref-type="fig" rid="gks615-F5">Figure 5</xref>B. It has been shown that mutation and overexpression in FGFR3 are associated with survival of melanoma patients (<xref ref-type="bibr" rid="gks615-B136">136</xref>). However, FGFR3 was not annotated in the melanoma pathway although it is interacting with several members in the pathway. The network views of all the 27 expanded KEGG disease pathways with newly predicted member genes are available at the article's Supplementary Web. These results support that R-NMTF correctly predicted new member genes in several disease-related pathways, and these novel disease genes could play important roles in the disease pathways.<fig id="gks615-F5" position="float"><label>Figure 5.</label><caption><p>PPI subnetworks of the extended disease pathways. In each pathway, gray nodes are known member genes in the disease pathways and red nodes are newly predicted member genes. Edges represent PPI between two genes. Note that if a known or a newly predicted member gene is not interacting with any other member genes in the pathway, the gene is not included. (<bold>A</bold>) Colorectal cancer pathway. The predicted colorectal cancer genes EXO1 and ADIPOR1 are interacting with many other genes in the colorectal cancer pathway. (<bold>B</bold>) Alzheimer pathway. Over-expression of C1R is known for involving alzheimer disease. (<bold>C</bold>) Melanoma pathway. Mutation and copy number changes in new member gene FGFR3 were recently discovered in melanoma.</p></caption><graphic xlink:href="gks615f5p"/></fig></p></sec><sec><title>Analysis of predicted disease phenotype cluster&#x02013;gene cluster associations</title><p>We evaluated the predicted disease phenotype cluster&#x02013;gene cluster associations by a literature survey. We performed two-way hierarchical clustering for the predicted disease phenotype cluster&#x02013;gene cluster associations. <xref ref-type="fig" rid="gks615-F6">Figure 6</xref> shows the predicted associations between 20 disease phenotype clusters and 200 gene clusters (pathways). Interesting examples are the manually curated KEGG disease pathways. These disease-related pathways include pathways related to cancers, neurological diseases and psychiatric diseases. R-NMTF accurately predicted association between many of these disease-related pathways to the related disease classes. For example, many cancer-related pathways including colorectal, pancreatic, bladder, non-small cell lung, glioma and prostate cancer were correctly identified as cancer pathways. We also identified a set of biological pathways such as apoptosis, p53 signaling and ERBB signaling, hedgehog signaling which are previously known to contribute to tumorigenesis, as well as targets of many anti-cancer drugs (<xref ref-type="bibr" rid="gks615-B137 gks615-B138 gks615-B139 gks615-B140 gks615-B141">137&#x02013;141</xref>). Other interesting examples are the pathways predicted to be associated to neurological and psychiatric disease classes. Prion disease is one of the well-known rare progressive neurodegenerative disorders that affect both humans and animals. R-NMTF accurately predicted the prion disease pathway as one of the pathways associated with neurological disease class. MAPK pathway is predicted to be associated with both neurological and psychiatric disease classes. Recent study reported that activation of MAPK pathway could play a role in alzheimer and psychiatric disorders such as increasing anxiety and depression and schizophrenia etc. (<xref ref-type="bibr" rid="gks615-B142">142</xref>,<xref ref-type="bibr" rid="gks615-B143">143</xref>). R-NMTF also correctly predicted Huntington's disease pathway to be associated with neurological and psychiatric diseases.<fig id="gks615-F6" position="float"><label>Figure 6.</label><caption><p>Predicted associations between disease classes and pathways. Each red entry represents a predicted association between 20 disease classes and 200 KEGG pathways.</p></caption><graphic xlink:href="gks615f6p"/></fig></p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The number of documented disease phenotypes and phenotype&#x02013;gene associations increases quickly. Since 2007, the number of OMIM disease&#x02013;gene associations is nearly doubled. These determined associations provide valuable resources not only for predicting novel associations but also for understanding disease phenotypes. Our research work in the article explored this possibility and reported promising results. Recently, phenotype databases have been proposed and in the progress of becoming comprehensive and systematic for many species. R-NMTF will be a useful model for analyzing the new &#x02018;phenomes&#x02019;. Moreover, R-NMTF also identifies pathways associated with disease phenotype clusters. Since many drugs are developed to target proteins that act in disease-related pathways, precise identification of members of disease pathways could accelerate the development of more efficient targeted therapies, as well as improve understanding of the molecular mechanisms underlying complex human diseases. More recently, cross-species phenotype&#x02013;gene association analysis based on ortholog genes and similar phenotypes has been performed (<xref ref-type="bibr" rid="gks615-B144">144</xref>). An interesting future direction is to extend R-NMTF to perform cross-species phenome&#x02013;genome co-clustering. It is also possible to apply other advanced machine learning models to integrate the phenotype similarity network and the PPI network with phenotype&#x02013;gene association data for co-clustering phenotypes and genes. More refined modeling might lead to further improvement in phenotype classification and disease&#x02013;gene discovery.</p><p>Previously, regularized NMTF models were only proposed for applications in image and document classification. Gu and Zhou (<xref ref-type="bibr" rid="gks615-B145">145</xref>) introduced a dual regularized co-clustering (DRCC), which extended NMTF by incorporating the graph Laplacian as additional regularizations in the objective function. DRCC was applied to classify images, documents and newsgroups. Zh vang <italic>et al.</italic> (<xref ref-type="bibr" rid="gks615-B38">38</xref>) introduced a matrix tri-factorization-based classification framework (MTrick) for transfer learning. MTrick first learns an association matrix from source domain by performing non-negative tri-factorization and use incorporates inferred association matrix <italic>S</italic> from source domain into non-negative tri-factorization for target domain classification. R-NMTF introduces regularization terms for label information from both phenotype and gene clusters, and thus R-NMTF is a supervised co-clustering method while DRCC is unsupervised. Compared with MTrick, which only uses label information, R-NMTF incorporates the prior knowledge in phenotype similarity network and PPI networks to cluster phenotypes and genes with tri-matrix factorization. To our best knowledge, no previous NMF-based model has been applied to clustering phenotypes or analyzing disease phenotype&#x02013;gene associations. R-NMTF is an advanced model which integrates phenome, genome and interactome information for both problems.</p></sec><sec><title>SUPPLEMENTARY DATA</title><p><ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkr615/DC1">Supplementary Data</ext-link> are available at NAR Online: <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkr615/DC1">Supplementary Tables 1 and 2</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkr615/DC1">Supplementary Figure 1</ext-link>.</p></sec><sec id="SEC6"><title>FUNDING</title><p>Funding for open access charge: <funding-source>National Science Foundation</funding-source> [<award-id>III-1117153</award-id>].</p><p><italic>Conflict of interest statement</italic>. None declared.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_40_19_e146__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_gks615_nar-00794-met-h-2012-File002.pdf"/>
</supplementary-material>
</sec>
</body><back><ref-list><title>REFERENCES</title><ref id="gks615-B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKusick</surname><given-names>V</given-names></name></person-group><article-title>Mendelian Inheritance in Man and its online version, OMIM</article-title><source>Am. J. Hum. Genet.</source><year>2007</year><volume>80</volume><fpage>588</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">17357067</pub-id></element-citation></ref><ref id="gks615-B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groth</surname><given-names>P</given-names></name><name><surname>Weiss</surname><given-names>B</given-names></name></person-group><article-title>Phenotype Data: a Neglected Resource in Biomedical Research?</article-title><source>Curr. Bioinformatics</source><year>2006</year><volume>1</volume><fpage>347</fpage><lpage>358</lpage></element-citation></ref><ref id="gks615-B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawyers</surname><given-names>C</given-names></name></person-group><article-title>The cancer biomarker problem</article-title><source>Nature</source><year>2008</year><volume>452</volume><fpage>548</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">18385728</pub-id></element-citation></ref><ref id="gks615-B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>E</given-names></name></person-group><article-title>Genomics of cellulosic biofuels</article-title><source>Nature</source><year>2008</year><volume>454</volume><fpage>841</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">18704079</pub-id></element-citation></ref><ref id="gks615-B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>D</given-names></name><name><surname>Batley</surname><given-names>J</given-names></name></person-group><article-title>Plant bioinformatics: from genome to phenome</article-title><source>Trends Biotechnol</source><year>2004</year><volume>22</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">15109809</pub-id></element-citation></ref><ref id="gks615-B6"><label>6</label><element-citation publication-type="book"><comment>The Wellcome Trust Case Control Consortium. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. <italic>Nature</italic>, <bold>447</bold>, 661&#x02013;678</comment></element-citation></ref><ref id="gks615-B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van't Veer</surname><given-names>L</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><article-title>Enabling personalized cancer medicine through analysis of gene-expression patterns</article-title><source>Nature</source><year>2008</year><volume>452</volume><fpage>564</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">18385730</pub-id></element-citation></ref><ref id="gks615-B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>O'Donnell</surname><given-names>C</given-names></name></person-group><article-title>An open access database of genome-wide association resutls</article-title><source>BMC Med. Gent.</source><year>2009</year><volume>6</volume></element-citation></ref><ref id="gks615-B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlien</surname><given-names>A</given-names></name><name><surname>Malkin</surname><given-names>D</given-names></name></person-group><article-title>Copy number variations and cancer</article-title><source>Genome Med.</source><year>2009</year><volume>1</volume><fpage>62</fpage><pub-id pub-id-type="pmid">19566914</pub-id></element-citation></ref><ref id="gks615-B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name></person-group><article-title>Next-generation DNA sequencing</article-title><source>Nat. Biotech.</source><year>2008</year><volume>26</volume><fpage>1135</fpage><lpage>1145</lpage></element-citation></ref><ref id="gks615-B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothberg</surname><given-names>J</given-names></name><name><surname>Leamon</surname><given-names>J</given-names></name></person-group><article-title>The development and impact of 454 sequencing</article-title><source>Nat. Biotechnol.</source><year>2008</year><volume>26</volume><fpage>1117</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">18846085</pub-id></element-citation></ref><ref id="gks615-B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>L</given-names></name><name><surname>van Bakel</surname><given-names>H</given-names></name><name><surname>Fokkens</surname><given-names>L</given-names></name><name><surname>de Jong</surname><given-names>E</given-names></name><name><surname>Egmont-Petersen</surname><given-names>M</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name></person-group><article-title>Reconstruction of a functional human gene network, with an application for prioritizing positional candidate genes</article-title><source>Am. J. Hum. Genet.</source><year>2006</year><volume>78</volume><fpage>1011</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">16685651</pub-id></element-citation></ref><ref id="gks615-B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Horn</surname><given-names>D</given-names></name><name><surname>Robinson</surname><given-names>P</given-names></name></person-group><article-title>Walking the interactome for prioritization of candidate disease genes</article-title><source>Am. J. Hum. Genet.</source><year>2008</year><volume>82</volume><fpage>949</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">18371930</pub-id></element-citation></ref><ref id="gks615-B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>Network-based global inference of human disease genes</article-title><source>Mol. Syst. Biol.</source><year>2008</year><volume>4</volume><fpage>189</fpage><pub-id pub-id-type="pmid">18463613</pub-id></element-citation></ref><ref id="gks615-B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linghu</surname><given-names>B</given-names></name><name><surname>Snitkin</surname><given-names>E</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Delisi</surname><given-names>C</given-names></name></person-group><article-title>Genome-wide prioritization of disease genes and identification of disease&#x02013;disease associations from an integrated human functional linkage network</article-title><source>Genome Biol.</source><year>2009</year><volume>10</volume><fpage>R91</fpage><pub-id pub-id-type="pmid">19728866</pub-id></element-citation></ref><ref id="gks615-B16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>T</given-names></name><name><surname>Kuang</surname><given-names>R</given-names></name></person-group><article-title>A Heterogeneous Label Propagation Algorithm for Disease Gene Discovery</article-title><source>Proc of SIAM International Conference on Data Mining</source><year>2010</year><fpage>583</fpage><lpage>594</lpage></element-citation></ref><ref id="gks615-B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanunu</surname><given-names>O</given-names></name><name><surname>Magger</surname><given-names>O</given-names></name><name><surname>Ruppin</surname><given-names>E</given-names></name><name><surname>Shlomi</surname><given-names>T</given-names></name><name><surname>Sharan</surname><given-names>R</given-names></name></person-group><article-title>Associating genes and protein complexes with disease via network propagation</article-title><source>PLoS Comput. Biol.</source><year>2010</year><volume>6</volume><fpage>e1000641</fpage><pub-id pub-id-type="pmid">20090828</pub-id></element-citation></ref><ref id="gks615-B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Patra</surname><given-names>J</given-names></name></person-group><article-title>Genome-wide inferring gene&#x02013;phenotype relationship by walking on the heterogeneous network</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>1219</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">20215462</pub-id></element-citation></ref><ref id="gks615-B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navlakha</surname><given-names>S</given-names></name><name><surname>Kingsford</surname><given-names>C</given-names></name></person-group><article-title>The power of protein interaction networks for associating genes with diseases</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>1057</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">20185403</pub-id></element-citation></ref><ref id="gks615-B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loscalzo</surname><given-names>J</given-names></name><name><surname>Kohane</surname><given-names>I</given-names></name><name><surname>Barabasi</surname><given-names>A</given-names></name></person-group><article-title>Human disease classification in the postgenomic era: a complex systems approach to human pathobiology</article-title><source>Mol. Syst. Biol.</source><year>2007</year><volume>3</volume><fpage>124</fpage><pub-id pub-id-type="pmid">17625512</pub-id></element-citation></ref><ref id="gks615-B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Driel</surname><given-names>M</given-names></name><name><surname>Bruggeman</surname><given-names>J</given-names></name><name><surname>Vriend</surname><given-names>G</given-names></name><name><surname>Brunner</surname><given-names>H</given-names></name><name><surname>Leunissen</surname><given-names>J</given-names></name></person-group><article-title>A text-mining analysis of the human phenome</article-title><source>Eur. J. Hum. Genet.</source><year>2006</year><volume>14</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">16493445</pub-id></element-citation></ref><ref id="gks615-B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freimer</surname><given-names>N</given-names></name><name><surname>Sabatti</surname><given-names>C</given-names></name></person-group><article-title>The human phenome project</article-title><source>Nat. Genet.</source><year>2003</year><volume>34</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12721547</pub-id></element-citation></ref><ref id="gks615-B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scriver</surname><given-names>C</given-names></name></person-group><article-title>After the genome&#x02013;the phenome?</article-title><source>J. Inherit. Metab. Dis.</source><year>2004</year><volume>27</volume><fpage>305</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">15190190</pub-id></element-citation></ref><ref id="gks615-B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groth</surname><given-names>P</given-names></name><name><surname>Kalev</surname><given-names>I</given-names></name><name><surname>Kirov</surname><given-names>I</given-names></name><name><surname>Traikov</surname><given-names>B</given-names></name><name><surname>Leser</surname><given-names>U</given-names></name><name><surname>Weiss</surname><given-names>B</given-names></name></person-group><article-title>Phenoclustering: online mining of cross-species phenotypes</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>1924</fpage><lpage>1925</lpage><pub-id pub-id-type="pmid">20562418</pub-id></element-citation></ref><ref id="gks615-B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goh</surname><given-names>K-I</given-names></name><name><surname>Cusick</surname><given-names>ME</given-names></name><name><surname>Valle</surname><given-names>D</given-names></name><name><surname>Childs</surname><given-names>B</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Barab&#x000e1;si</surname><given-names>A-L</given-names></name></person-group><article-title>The human disease network</article-title><source>Proc Natl Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>8685</fpage><lpage>8690</lpage><pub-id pub-id-type="pmid">17502601</pub-id></element-citation></ref><ref id="gks615-B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barabasi</surname><given-names>A</given-names></name><name><surname>Gulbahce</surname><given-names>N</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><article-title>Network medicine: a network-based approach to human disease</article-title><source>Nat. Rev. Genet.</source><year>2011</year><volume>12</volume><fpage>56</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">21164525</pub-id></element-citation></ref><ref id="gks615-B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Kawashima</surname><given-names>S</given-names></name><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name></person-group><article-title>The KEGG resource for deciphering the genome</article-title><source>Nucleic Acids Res</source><year>2004</year><volume>32</volume><fpage>D277</fpage><lpage>D280</lpage><pub-id pub-id-type="pmid">14681412</pub-id></element-citation></ref><ref id="gks615-B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Seung</surname><given-names>H</given-names></name></person-group><article-title>Learning the parts of objects by non-negative matrix factorization</article-title><source>Nature</source><year>1999</year><volume>401</volume><fpage>788</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">10548103</pub-id></element-citation></ref><ref id="gks615-B29"><label>29</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DD</given-names></name><name><surname>Seung</surname><given-names>HS</given-names></name></person-group><source>The proceeding of Neural Information Processing Systems</source><year>2000</year><publisher-loc>Denver, CO, USA</publisher-loc><publisher-name>MIT Press</publisher-name><fpage>556</fpage><lpage>562</lpage></element-citation></ref><ref id="gks615-B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname><given-names>J</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Golub</surname><given-names>T</given-names></name><name><surname>Mesirov</surname><given-names>J</given-names></name></person-group><article-title>Metagenes and molecular pattern discovery using matrix factorization</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>4164</fpage><lpage>4169</lpage><pub-id pub-id-type="pmid">15016911</pub-id></element-citation></ref><ref id="gks615-B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Drake</surname><given-names>B</given-names></name></person-group><article-title>Extracting unrecognized gene relationships from the biomedical literature via matrix factorizations</article-title><source>BMC Bioinformatics</source><year>2007</year><volume>8</volume><issue>Suppl 9</issue><fpage>S6</fpage><pub-id pub-id-type="pmid">18047707</pub-id></element-citation></ref><ref id="gks615-B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schachtner</surname><given-names>R</given-names></name><name><surname>Lutter</surname><given-names>D</given-names></name><name><surname>Knollmuller</surname><given-names>P</given-names></name><name><surname>Tome</surname><given-names>A</given-names></name><name><surname>Theis</surname><given-names>F</given-names></name><name><surname>Schmitz</surname><given-names>G</given-names></name><name><surname>Stetter</surname><given-names>M</given-names></name><name><surname>Vilda</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>E</given-names></name></person-group><article-title>Knowledge-based gene expression classification via matrix factorization</article-title><source>Bioinformatics</source><year>2008</year><volume>24</volume><fpage>1688</fpage><lpage>1697</lpage><pub-id pub-id-type="pmid">18535085</pub-id></element-citation></ref><ref id="gks615-B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>H</given-names></name></person-group><article-title>Sparse non-negative matrix factorizations via alternating non-negativity-constrained least squares for microarray data analysis</article-title><source>Bioinformatics</source><year>2007</year><volume>23</volume><fpage>1495</fpage><lpage>1502</lpage><pub-id pub-id-type="pmid">17483501</pub-id></element-citation></ref><ref id="gks615-B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inamura</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>T</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Isagawa</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Virtanen</surname><given-names>C</given-names></name><name><surname>Shimane</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>Y</given-names></name><name><surname>Okumura</surname><given-names>S</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>7105</fpage><lpage>7113</lpage><pub-id pub-id-type="pmid">16007138</pub-id></element-citation></ref><ref id="gks615-B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>D</given-names></name><name><surname>Cagney</surname><given-names>G</given-names></name><name><surname>Krogan</surname><given-names>N</given-names></name><name><surname>Cunningham</surname><given-names>P</given-names></name></person-group><article-title>Ensemble non-negative matrix factorization methods for clustering protein&#x02013;protein interactions</article-title><source>Bioinformatics</source><year>2008</year><volume>24</volume><fpage>1722</fpage><lpage>1728</lpage><pub-id pub-id-type="pmid">18556670</pub-id></element-citation></ref><ref id="gks615-B36"><label>36</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>H</given-names></name></person-group><source>Proceeding of the 12th ACM International Conference on Knowledge Discovery and Data Mining</source><year>2006</year><publisher-loc>Philadelphia, PA, USA</publisher-loc><publisher-name>ACM (Association for Computing Machinery)</publisher-name><fpage>126</fpage><lpage>135</lpage></element-citation></ref><ref id="gks615-B37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Sindhwani</surname><given-names>V</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><source>SIAM Conference on Data Mining</source><year>2010</year><publisher-loc>Columbus, Ohio, USA</publisher-loc><publisher-name>SIAM (Society for Industrial and Applied Mathematics)</publisher-name><fpage>293</fpage><lpage>302</lpage></element-citation></ref><ref id="gks615-B38"><label>38</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>P</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name></person-group><source>SIAM Conference on Data Mining</source><year>2010</year><publisher-name>Press</publisher-name><fpage>13</fpage><lpage>24</lpage></element-citation></ref><ref id="gks615-B39"><label>39</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>F</given-names></name></person-group><article-title>Spectral graph theory</article-title><source><italic>In:</italic> Regional Conference Series in Mathematics</source><year>1997</year><volume>Vol. 92</volume><publisher-loc>Providence, RI, Ann Arbor, MI</publisher-loc><publisher-name>American Mathematical Society</publisher-name></element-citation></ref><ref id="gks615-B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>M</given-names></name><name><surname>Claremont</surname><given-names>M</given-names></name><name><surname>Major</surname><given-names>J</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Lash</surname><given-names>A</given-names></name></person-group><article-title>CancerGenes: a gene selection resource for cancer genome projects</article-title><source>Nucleic Acids Res</source><year>2007</year><volume>35</volume><fpage>D721</fpage><lpage>D726</lpage><pub-id pub-id-type="pmid">17088289</pub-id></element-citation></ref><ref id="gks615-B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peri</surname><given-names>S</given-names></name><name><surname>Navarro</surname><given-names>J</given-names></name><name><surname>Amanchy</surname><given-names>R</given-names></name><name><surname>Kristiansen</surname><given-names>T</given-names></name><name><surname>Jonnalagadda</surname><given-names>C</given-names></name><name><surname>Surendranath</surname><given-names>V</given-names></name><name><surname>Niranjan</surname><given-names>V</given-names></name><name><surname>Muthusamy</surname><given-names>B</given-names></name><name><surname>Gandhi</surname><given-names>T</given-names></name><name><surname>Gronborg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of human protein reference database as an initial platform for approaching systems biology in humans</article-title><source>Genome Res</source><year>2003</year><volume>13</volume><fpage>2363</fpage><lpage>2371</lpage><pub-id pub-id-type="pmid">14525934</pub-id></element-citation></ref><ref id="gks615-B42"><label>42</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Bousquet</surname><given-names>O</given-names></name><name><surname>Lal</surname><given-names>TN</given-names></name><name><surname>Weston</surname><given-names>J</given-names></name><name><surname>Schlkopf</surname><given-names>B</given-names></name></person-group><source><italic>In</italic> Advances in Neural Information Processing Systems 16</source><year>2004</year><publisher-name>MIT Press</publisher-name><fpage>321</fpage><lpage>328</lpage></element-citation></ref><ref id="gks615-B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>P</given-names></name><name><surname>Mundlos</surname><given-names>S</given-names></name></person-group><article-title>The human phenotype ontology</article-title><source>Clin. Genet.</source><year>2010</year><volume>77</volume><fpage>525</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">20412080</pub-id></element-citation></ref><ref id="gks615-B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>CM</given-names></name></person-group><article-title>International nosology and classification of constitutional disorders of bone (2001)</article-title><source>Am. J. Med. Genet.</source><year>2002</year><volume>113</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">12400068</pub-id></element-citation></ref><ref id="gks615-B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCulloch</surname><given-names>KJ</given-names></name><name><surname>Mills</surname><given-names>CM</given-names></name><name><surname>Greenfeld</surname><given-names>RS</given-names></name><name><surname>Coil</surname><given-names>JM</given-names></name></person-group><article-title>Dens evaginatus from an orthodontic perspective: report of several clinical cases and review of the literature</article-title><source>Am. J. Orthod. Dentofacial Orthop.</source><year>1997</year><volume>112</volume><fpage>670</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">9423700</pub-id></element-citation></ref><ref id="gks615-B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Cahill</surname><given-names>DR</given-names></name></person-group><article-title>Regional control by the dental follicle of alterations in alveolar bone metabolism during tooth eruption</article-title><source>J. Oral Pathol. Med.</source><year>1987</year><volume>16</volume><fpage>164</fpage><lpage>169</lpage></element-citation></ref><ref id="gks615-B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>ME</given-names></name><name><surname>Augsburger</surname><given-names>RH</given-names></name></person-group><article-title>Dentine dysplasia with sclerotic bone and skeletal anomalies inherited as an autosomal dominant trait: a new syndrome</article-title><source>Oral Surg. Oral Med. Oral Patho.</source><year>1977</year><volume>43</volume><fpage>267</fpage><lpage>283</lpage></element-citation></ref><ref id="gks615-B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Susceptibility pathways in fanconi's anemia and breast cancer</article-title><source>N. Engl J. Med.</source><year>2010</year><volume>362</volume><fpage>1909</fpage><lpage>1919</lpage><pub-id pub-id-type="pmid">20484397</pub-id></element-citation></ref><ref id="gks615-B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>A</given-names></name><name><surname>Hamel</surname><given-names>N</given-names></name><name><surname>Schwartz</surname><given-names>CE</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name><name><surname>Harper</surname><given-names>JI</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name></person-group><article-title>A genome-wide analysis of loss of heterozygosity and chromosomal copy number variation in Proteus syndrome using high-density SNP microarrays</article-title><source>J. Hum. Genet.</source><year>2010</year><volume>55</volume><fpage>627</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">20555334</pub-id></element-citation></ref><ref id="gks615-B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahcall</surname><given-names>O</given-names></name></person-group><article-title>Proteus syndrome exomes</article-title><source>Nat. Genet.</source><year>2011</year><volume>43</volume><fpage>824</fpage><lpage>824</lpage></element-citation></ref><ref id="gks615-B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindhurst</surname><given-names>MJ</given-names></name><name><surname>Sapp</surname><given-names>JC</given-names></name><name><surname>Teer</surname><given-names>JK</given-names></name><name><surname>Johnston</surname><given-names>JJ</given-names></name><name><surname>Finn</surname><given-names>EM</given-names></name><name><surname>Peters</surname><given-names>K</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Cannons</surname><given-names>JL</given-names></name><name><surname>Bick</surname><given-names>D</given-names></name><name><surname>Blakemore</surname><given-names>L</given-names></name><etal/></person-group><article-title>A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome</article-title><source>New Engl. Jo. Med.</source><year>2011</year><volume>365</volume><fpage>611</fpage><lpage>619</lpage></element-citation></ref><ref id="gks615-B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zbuk</surname><given-names>KM</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Cancer phenomics: RET and PTEN as illustrative models</article-title><source>Nat. Rev. Cancer.</source><year>2007</year><volume>7</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">17167516</pub-id></element-citation></ref><ref id="gks615-B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilarski</surname><given-names>R</given-names></name><name><surname>Stephens</surname><given-names>JA</given-names></name><name><surname>Noss</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>JL</given-names></name><name><surname>Prior</surname><given-names>TW</given-names></name></person-group><article-title>Predicting PTEN mutations: an evaluation of Cowden syndrome and bannayanrileyruvalcaba syndrome clinical features</article-title><source>J. Med. Genet.</source><year>2011</year><volume>48</volume><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">21659347</pub-id></element-citation></ref><ref id="gks615-B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patnaik</surname><given-names>MM</given-names></name><name><surname>Raza</surname><given-names>SS</given-names></name><name><surname>Khambatta</surname><given-names>S</given-names></name><name><surname>Stanich</surname><given-names>PP</given-names></name><name><surname>Goetz</surname><given-names>MP</given-names></name></person-group><article-title>Oncophenotypic Review and Clinical Correlates of Phosphatase and Tensin Homolog on Chromosome 10 Hamartoma Tumor Syndrome</article-title><source>J. Clini. Oncol.</source><year>2010</year><volume>28</volume><fpage>e767</fpage><lpage>e768</lpage></element-citation></ref><ref id="gks615-B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groenewegen</surname><given-names>WA</given-names></name><name><surname>Firouzi</surname><given-names>M</given-names></name><name><surname>Bezzina</surname><given-names>CR</given-names></name><name><surname>Vliex</surname><given-names>S</given-names></name><name><surname>van Langen</surname><given-names>IM</given-names></name><name><surname>Sandkuijl</surname><given-names>L</given-names></name><name><surname>Smits</surname><given-names>JP</given-names></name><name><surname>Hulsbeek</surname><given-names>M</given-names></name><name><surname>Rook</surname><given-names>MB</given-names></name><name><surname>Jongsma</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>A Cardiac Sodium Channel Mutation Cosegregates With a Rare Connexin40 Genotype in Familial Atrial Standstill</article-title><source>Circ. Res.</source><year>2003</year><volume>92</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12522116</pub-id></element-citation></ref><ref id="gks615-B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roden</surname><given-names>DM</given-names></name></person-group><article-title>Long-QT Syndrome</article-title><source>New Engl. J. Med.</source><year>2008</year><volume>358</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">18184962</pub-id></element-citation></ref><ref id="gks615-B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotti</surname><given-names>L</given-names></name><name><surname>Monti</surname><given-names>MC</given-names></name><name><surname>Insolia</surname><given-names>R</given-names></name><name><surname>Peljto</surname><given-names>A</given-names></name><name><surname>Goosen</surname><given-names>A</given-names></name><name><surname>Brink</surname><given-names>PA</given-names></name><name><surname>Greenberg</surname><given-names>DA</given-names></name><name><surname>Schwartz</surname><given-names>PJ</given-names></name><name><surname>George</surname><given-names>AL</given-names></name></person-group><article-title>NOS1AP Is a Genetic Modifier of the Long-QT Syndrome</article-title><source>Circulation</source><year>2009</year><volume>120</volume><fpage>1657</fpage><lpage>1663</lpage><pub-id pub-id-type="pmid">19822806</pub-id></element-citation></ref><ref id="gks615-B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horne</surname><given-names>RSC</given-names></name><name><surname>Witcombe</surname><given-names>NB</given-names></name><name><surname>Yiallourou</surname><given-names>SR</given-names></name><name><surname>Scaillet</surname><given-names>S</given-names></name><name><surname>Thiriez</surname><given-names>G</given-names></name><name><surname>Franco</surname><given-names>P</given-names></name></person-group><article-title>Cardiovascular control during sleep in infants: implications for Sudden Infant Death Syndrome</article-title><source>Sleep Medicine</source><year>2010</year><volume>11</volume><fpage>615</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">20609624</pub-id></element-citation></ref><ref id="gks615-B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>RM</given-names></name><name><surname>O'Connell</surname><given-names>DJ</given-names></name></person-group><article-title>The arthritis of mixed connective tissue disease</article-title><source>Ann. Rheumatic Diseases</source><year>1978</year><volume>37</volume><fpage>397</fpage><lpage>403</lpage></element-citation></ref><ref id="gks615-B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcafee</surname><given-names>PC</given-names></name><name><surname>Cady</surname><given-names>RB</given-names></name></person-group><article-title>Endocrinologic and Metabolic Factors in Atypical Presentations of Slipped Capital Femoral Epiphysis: Report of Four Cases and Review of the Literature</article-title><source>Clin. Orthopa. Relat Res.</source><year>1983</year><volume>180</volume></element-citation></ref><ref id="gks615-B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>A</given-names></name><name><surname>Sah</surname><given-names>K</given-names></name><name><surname>Rastogi</surname><given-names>P</given-names></name><name><surname>Awasthi</surname><given-names>S</given-names></name><name><surname>Chandra</surname><given-names>S</given-names></name></person-group><article-title>Traumatic pseudolipoma causing facial asymmetry: an uncommon pathology and review of its pathogenesis</article-title><source>J. Oral Maxillofacial Pathol.</source><year>2011</year><volume>15</volume><fpage>113</fpage><lpage>115</lpage></element-citation></ref><ref id="gks615-B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai-Cheong</surname><given-names>JE</given-names></name><name><surname>Arita</surname><given-names>K</given-names></name><name><surname>McGrath</surname><given-names>JA</given-names></name></person-group><article-title>Genetic Diseases of Junctions</article-title><source>J. Invest Dermatol</source><volume>127</volume><fpage>2713</fpage><lpage>2725</lpage><pub-id pub-id-type="pmid">18007692</pub-id></element-citation></ref><ref id="gks615-B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leachman</surname><given-names>SA</given-names></name><name><surname>Kaspar</surname><given-names>RL</given-names></name><name><surname>Fleckman</surname><given-names>P</given-names></name><name><surname>Florell</surname><given-names>SR</given-names></name><name><surname>Smith</surname><given-names>FJD</given-names></name><name><surname>McLean</surname><given-names>WHI</given-names></name><name><surname>Lunny</surname><given-names>DP</given-names></name><name><surname>Milstone</surname><given-names>LM</given-names></name><name><surname>van Steensel</surname><given-names>MAM</given-names></name><name><surname>Munro</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Clinical and Pathological Features of Pachyonychia Congenita</article-title><source>J. Investig. Dermatol. Symp. Proc.</source><year>2005</year><volume>10</volume><fpage>3</fpage><lpage>17</lpage></element-citation></ref><ref id="gks615-B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaoita</surname><given-names>H</given-names></name><name><surname>Briggaman</surname><given-names>RA</given-names></name><name><surname>Lawley</surname><given-names>TJ</given-names></name><name><surname>Provost</surname><given-names>TT</given-names></name><name><surname>Katz</surname><given-names>SI</given-names></name></person-group><article-title>Epidermolysis Bullosa Acquisita: Ultrastructural and Immunological Studies</article-title><source>J. Investig. Dermatol.</source><year>1981</year><volume>76</volume><fpage>288</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">7009764</pub-id></element-citation></ref><ref id="gks615-B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saravelos</surname><given-names>SH</given-names></name><name><surname>Cocksedge</surname><given-names>KA</given-names></name><name><surname>Li</surname><given-names>T-C</given-names></name></person-group><article-title>Prevalence and diagnosis of congenital uterine anomalies in women with reproductive failure: a critical appraisal</article-title><source>Hum. Reproduct. Update</source><year>2008</year><volume>14</volume><fpage>415</fpage><lpage>429</lpage></element-citation></ref><ref id="gks615-B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergada</surname><given-names>C</given-names></name><name><surname>Cleveland</surname><given-names>WW</given-names></name><name><surname>Jones</surname><given-names>HW</given-names></name><name><surname>Wilkins</surname><given-names>L</given-names></name></person-group><article-title>Variants of embryonic testicular dysgenesis: Bilateral anorchia and the syndrome of rudimentary testes</article-title><source>Acta Endocrinologica.</source><year>1962</year><volume>40</volume><fpage>521</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">13867602</pub-id></element-citation></ref><ref id="gks615-B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M-H</given-names></name><name><surname>Baskin</surname><given-names>LS</given-names></name></person-group><article-title>Endocrine Disruptors, Genital Development, and Hypospadias</article-title><source>J. Androl.</source><year>2008</year><volume>29</volume><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">18497336</pub-id></element-citation></ref><ref id="gks615-B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruedi</surname><given-names>L</given-names></name></person-group><article-title>Pathogenesis of Otosclerosis</article-title><source>Arch. Otolaryngol.</source><year>1963</year><volume>78</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">14059345</pub-id></element-citation></ref><ref id="gks615-B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerich</surname><given-names>JE</given-names></name><name><surname>Mokan</surname><given-names>M</given-names></name><name><surname>Veneman</surname><given-names>T</given-names></name><name><surname>Korytkowski</surname><given-names>M</given-names></name><name><surname>Mitrakou</surname><given-names>A</given-names></name></person-group><article-title>Hypoglycemia Unawareness</article-title><source>Endocrine Rev.</source><year>1991</year><volume>12</volume><fpage>356</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">1760993</pub-id></element-citation></ref><ref id="gks615-B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franks</surname><given-names>S</given-names></name></person-group><article-title>Polycystic Ovary Syndrome</article-title><source>New Eng. J. Med.</source><year>1995</year><volume>333</volume><fpage>853</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">7651477</pub-id></element-citation></ref><ref id="gks615-B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krohn</surname><given-names>K</given-names></name><name><surname>Fhrer</surname><given-names>D</given-names></name><name><surname>Bayer</surname><given-names>Y</given-names></name><name><surname>Eszlinger</surname><given-names>M</given-names></name><name><surname>Brauer</surname><given-names>V</given-names></name><name><surname>Neumann</surname><given-names>S</given-names></name><name><surname>Paschke</surname><given-names>R</given-names></name></person-group><article-title>Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter</article-title><source>Endocrine Rev.</source><year>2005</year><volume>26</volume><fpage>504</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">15615818</pub-id></element-citation></ref><ref id="gks615-B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcrae</surname><given-names>CA</given-names></name><name><surname>Prince</surname><given-names>MI</given-names></name><name><surname>Hudson</surname><given-names>M</given-names></name><name><surname>Day</surname><given-names>CP</given-names></name><name><surname>James</surname><given-names>OFW</given-names></name><name><surname>Jones</surname><given-names>DEJ</given-names></name></person-group><article-title>Pain as a complication of use of opiate antagonists for symptom control in cholestasis</article-title><source>Gastroenterology</source><year>2003</year><volume>125</volume><fpage>591</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">12891561</pub-id></element-citation></ref><ref id="gks615-B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowenfels</surname><given-names>AB</given-names></name><name><surname>Maisonneuve</surname><given-names>P</given-names></name><name><surname>DiMagno</surname><given-names>EP</given-names></name><name><surname>Elitsur</surname><given-names>Y</given-names></name><name><surname>Gates</surname><given-names>LK</given-names></name><name><surname>Perrault</surname><given-names>J</given-names></name><name><surname>Whitcomb</surname><given-names>DC</given-names></name></person-group><article-title>Hereditary Pancreatitis and the Risk of Pancreatic Cancer</article-title><source>J. Nat. Cancer Instit.</source><year>1997</year><volume>89</volume><fpage>442</fpage><lpage>446</lpage></element-citation></ref><ref id="gks615-B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayabose</surname><given-names>S</given-names></name><name><surname>Tugal</surname><given-names>O</given-names></name><name><surname>Sandoval</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Puder</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Visintainer</surname><given-names>P</given-names></name></person-group><article-title>Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia</article-title><source>The Journal of Pediatrics</source><year>1996</year><volume>129</volume><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">8859263</pub-id></element-citation></ref><ref id="gks615-B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiske</surname><given-names>DN</given-names></name><name><surname>McCoy</surname><given-names>HE</given-names></name><name><surname>Kitchens</surname><given-names>CS</given-names></name></person-group><article-title>Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome</article-title><source>Ame. J. Hematol.</source><year>1994</year><volume>46</volume><fpage>147</fpage><lpage>150</lpage></element-citation></ref><ref id="gks615-B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourne</surname><given-names>MS</given-names></name><name><surname>Elves</surname><given-names>MW</given-names></name><name><surname>Israls</surname><given-names>MCG</given-names></name></person-group><article-title>Familial Pyridoxine-Responsive Anaemia</article-title><source>Brit. J. Haematol.</source><year>1965</year><volume>11</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14252104</pub-id></element-citation></ref><ref id="gks615-B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enbom</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>F-Z</given-names></name><name><surname>Fredrikson</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Dahl</surname><given-names>H</given-names></name><name><surname>Linde</surname><given-names>A</given-names></name></person-group><article-title>Similar Humoral and Cellular Immunological Reactivities to Human Herpesvirus 6 in Patients with Multiple Sclerosis and Controls</article-title><source>Clin. Diagn. Lab. Immunol.</source><year>1999</year><volume>6</volume><fpage>545</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">10391860</pub-id></element-citation></ref><ref id="gks615-B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durum</surname><given-names>SK</given-names></name><name><surname>Schmidt</surname><given-names>JA</given-names></name><name><surname>Oppenheim</surname><given-names>JJ</given-names></name></person-group><article-title>Interleukin 1: an Immunological Perspective</article-title><source>Annu. Rev. Immunol.</source><year>1985</year><volume>3</volume><fpage>263</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">2933048</pub-id></element-citation></ref><ref id="gks615-B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>M</given-names></name><name><surname>Colby</surname><given-names>TV</given-names></name><name><surname>Kitaichi</surname><given-names>M</given-names></name></person-group><article-title>Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations</article-title><source>Human Pathol.</source><year>1994</year><volume>25</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">8163268</pub-id></element-citation></ref><ref id="gks615-B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>M</given-names></name><name><surname>Patterson</surname><given-names>R</given-names></name><name><surname>Mintzer</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>BJ</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>KE</given-names></name></person-group><article-title>Clinical and Immunologic Criteria for the Diagnosis of Allergic Bronchopulmonary Aspergillosis</article-title><source>Ann. Inter. Medi.</source><year>1977</year><volume>86</volume><fpage>405</fpage><lpage>414</lpage></element-citation></ref><ref id="gks615-B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorillo</surname><given-names>L</given-names></name></person-group><article-title>Therapy of pediatric genital diseases</article-title><source>Dermatologic Therapy</source><year>2004</year><volume>17</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">14756896</pub-id></element-citation></ref><ref id="gks615-B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malcolm</surname><given-names>P</given-names></name></person-group><article-title>Nutrition and schizophrenia: beyond omega-3 fatty acids</article-title><source>Prostaglandins Leukot. Essent. Fatty Acids</source><year>2004</year><volume>70</volume><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">15041037</pub-id></element-citation></ref><ref id="gks615-B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desport</surname><given-names>JC</given-names></name><name><surname>Preux</surname><given-names>PM</given-names></name><name><surname>Magy</surname><given-names>L</given-names></name><name><surname>Boirie</surname><given-names>Y</given-names></name><name><surname>Vallat</surname><given-names>JM</given-names></name><name><surname>Beaufrre</surname><given-names>B</given-names></name><name><surname>Couratier</surname><given-names>P</given-names></name></person-group><article-title>Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis</article-title><source>Am. J. Clin. Nutr.</source><year>2001</year><volume>74</volume><fpage>328</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">11522556</pub-id></element-citation></ref><ref id="gks615-B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>JM</given-names></name><name><surname>Clark</surname><given-names>RD</given-names></name><name><surname>Moeschler</surname><given-names>JB</given-names></name><name><surname>Rogers</surname><given-names>RC</given-names></name></person-group><article-title>Behavioral features in young adults with FG syndrome (OpitzKaveggia syndrome)</article-title><source>Am. J. Med. Genet. C Seminar Med. Genet.</source><year>2010</year><volume>154C</volume><fpage>477</fpage><lpage>485</lpage></element-citation></ref><ref id="gks615-B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petry</surname><given-names>NM</given-names></name><name><surname>Stinson</surname><given-names>FS</given-names></name><name><surname>Grant</surname><given-names>BF</given-names></name></person-group><article-title>Comorbidity of DSM-IV Pathological Gambling and Other Psychiatric Disorders: results From the National Epidemiologic Survey on Alcohol and Related Conditions</article-title><source>J. Clin. Psychiatr.</source><year>2005</year><volume>66</volume><fpage>564</fpage><lpage>574</lpage></element-citation></ref><ref id="gks615-B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaszczynski</surname><given-names>A</given-names></name><name><surname>Nower</surname><given-names>L</given-names></name></person-group><article-title>A pathways model of problem and pathological gambling</article-title><source>Addiction</source><year>2002</year><volume>97</volume><fpage>487</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">12033650</pub-id></element-citation></ref><ref id="gks615-B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blainey</surname><given-names>J</given-names></name><name><surname>Brewer</surname><given-names>D</given-names></name><name><surname>Hardwicke</surname><given-names>J</given-names></name><name><surname>Soothill</surname><given-names>J</given-names></name></person-group><article-title>The nephrotic syndrome. Diagnosis by renal biopsy and biochemical and immunological analyses related to the response to steroid therapy</article-title><source>Quart. j. Med.</source><year>1960</year><volume>29</volume><fpage>235</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">13801232</pub-id></element-citation></ref><ref id="gks615-B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boute</surname><given-names>N</given-names></name><name><surname>Gribouval</surname><given-names>O</given-names></name><name><surname>Roselli</surname><given-names>S</given-names></name><name><surname>Benessy</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Fuchshuber</surname><given-names>A</given-names></name><name><surname>Dahan</surname><given-names>K</given-names></name><name><surname>Gubler</surname><given-names>M-C</given-names></name><name><surname>Niaudet</surname><given-names>P</given-names></name><name><surname>Antignac</surname><given-names>C</given-names></name></person-group><article-title>NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome</article-title><source>Nat. Genet.</source><year>2000</year><volume>24</volume><fpage>349</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">10742096</pub-id></element-citation></ref><ref id="gks615-B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>BM</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name><name><surname>de Zeeuw</surname><given-names>D</given-names></name><name><surname>Keane</surname><given-names>WF</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Parving</surname><given-names>H-H</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name><name><surname>Snapinn</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Shahinfar</surname><given-names>S</given-names></name></person-group><article-title>Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy</article-title><source>New Eng. J. Med.</source><year>2001</year><volume>345</volume><fpage>861</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">11565518</pub-id></element-citation></ref><ref id="gks615-B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natochin</surname><given-names>YV</given-names></name><name><surname>Kuznetsova</surname><given-names>AA</given-names></name></person-group><article-title>Nocturnal enuresis: correction of renal function by desmopressin and diclofenac</article-title><source>Pediatr. Nephrol.</source><year>2000</year><volume>14</volume><fpage>42</fpage><lpage>47</lpage><comment>10.1007/s004670050011</comment><pub-id pub-id-type="pmid">10654330</pub-id></element-citation></ref><ref id="gks615-B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>M</given-names></name><name><surname>Clarren</surname><given-names>SK</given-names></name><name><surname>Zorn</surname><given-names>R</given-names></name><name><surname>Opitz</surname><given-names>JM</given-names></name></person-group><article-title>Isolated tibial hemimelia in sibs: an autosomal-recessive disorder?</article-title><source>Am. J. Med. Genet.</source><year>1984</year><volume>17</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">6711611</pub-id></element-citation></ref><ref id="gks615-B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koehn</surname><given-names>J</given-names></name><name><surname>Fountoulakis</surname><given-names>M</given-names></name><name><surname>Krapfenbauer</surname><given-names>K</given-names></name></person-group><article-title>Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance</article-title><source>Infect. Disorders Drug Targets (Formerly Current Drug Targets-Infectious</source><year>2008</year><volume>8</volume><fpage>109</fpage><lpage>118</lpage></element-citation></ref><ref id="gks615-B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilbronn</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Ravussin</surname><given-names>E</given-names></name></person-group><article-title>Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus</article-title><source>Int. J. Obe.</source><year>2004</year><volume>28</volume><fpage>S12</fpage><lpage>S21</lpage></element-citation></ref><ref id="gks615-B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>L</given-names></name><name><surname>Petersen</surname><given-names>G</given-names></name><name><surname>St&#x000e5;hl</surname><given-names>F</given-names></name></person-group><article-title>Ranking candidate genes in rat models of type 2 diabetes</article-title><source>Theor. Biol. Med. Mode.</source><year>2009</year><volume>6</volume><fpage>12</fpage></element-citation></ref><ref id="gks615-B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planas</surname><given-names>R</given-names></name><name><surname>Carrillo</surname><given-names>J</given-names></name><name><surname>Sanchez</surname><given-names>A</given-names></name><name><surname>Ruiz de Villa</surname><given-names>M</given-names></name><name><surname>Nu&#x000f1;ez</surname><given-names>F</given-names></name><name><surname>Verdaguer</surname><given-names>J</given-names></name><name><surname>James</surname><given-names>R</given-names></name><name><surname>Pujol-Borrell</surname><given-names>R</given-names></name><name><surname>Vives-Pi</surname><given-names>M</given-names></name></person-group><article-title>Gene expression profiles for the human pancreas and purified islets in Type 1 diabetes: new findings at clinical onset and in long-standing diabetes</article-title><source>Clini. Exp. Immunol.</source><year>2010</year><volume>159</volume><fpage>23</fpage><lpage>44</lpage></element-citation></ref><ref id="gks615-B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donner</surname><given-names>H</given-names></name><name><surname>Rau</surname><given-names>H</given-names></name><name><surname>Walfish</surname><given-names>P</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Siegmund</surname><given-names>T</given-names></name><name><surname>Finke</surname><given-names>R</given-names></name><name><surname>Herwig</surname><given-names>J</given-names></name><name><surname>Usadel</surname><given-names>K</given-names></name><name><surname>Badenhoop</surname><given-names>K</given-names></name></person-group><article-title>CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus</article-title><source>J. Clin. Endocrinol. Metab.</source><year>1997</year><volume>82</volume><fpage>143</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">8989248</pub-id></element-citation></ref><ref id="gks615-B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haygood</surname><given-names>R</given-names></name><name><surname>Fedrigo</surname><given-names>O</given-names></name><name><surname>Hanson</surname><given-names>B</given-names></name><name><surname>Yokoyama</surname><given-names>K</given-names></name><name><surname>Wray</surname><given-names>G</given-names></name></person-group><article-title>Promoter regions of many neural-and nutrition-related genes have experienced positive selection during human evolution</article-title><source>Nat. Genet.</source><year>2007</year><volume>39</volume><fpage>1140</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">17694055</pub-id></element-citation></ref><ref id="gks615-B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanzi</surname><given-names>R</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name></person-group><article-title>Twenty years of the Alzheimers disease amyloid hypothesis: a genetic perspective</article-title><source>Cell</source><year>2005</year><volume>120</volume><fpage>545</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">15734686</pub-id></element-citation></ref><ref id="gks615-B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>C</given-names></name></person-group><article-title>Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: app, cholesterol, lipoproteins, and atherosclerosis</article-title><source>Neurochem. Int.</source><year>2007</year><volume>50</volume><fpage>12</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">16973241</pub-id></element-citation></ref><ref id="gks615-B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vrij</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>D</given-names></name><name><surname>Van Leeuwen</surname><given-names>F</given-names></name><name><surname>Hol</surname><given-names>E</given-names></name></person-group><article-title>Protein quality control in Alzheimer's disease by the ubiquitin proteasome system</article-title><source>Prog. neurobiol.</source><year>2004</year><volume>74</volume><fpage>249</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">15582222</pub-id></element-citation></ref><ref id="gks615-B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parelkar</surname><given-names>S</given-names></name><name><surname>Cadena</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sugal</surname><given-names>R</given-names></name><name><surname>Bentley</surname><given-names>B</given-names></name><name><surname>Moral</surname><given-names>L</given-names></name><name><surname>Ardley</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>L</given-names></name></person-group><article-title>The Parkin-Like Human Homolog of Drosophila Ariadne-1 (HHARI) Can Induce Aggresome Formation in Mammalian Cells and Is Immunologically Detectable in Lewy Bodies</article-title><source>J. Mol. Neurosci.</source><year>2012</year><volume>46</volume><fpage>109</fpage><lpage>121</lpage><comment>10.1007/s12031-011-9535-1</comment><pub-id pub-id-type="pmid">21590270</pub-id></element-citation></ref><ref id="gks615-B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadano</surname><given-names>S</given-names></name><name><surname>Otomo</surname><given-names>A</given-names></name><name><surname>Suzuki-Utsunomiya</surname><given-names>K</given-names></name><name><surname>Kunita</surname><given-names>R</given-names></name><name><surname>Yanagisawa</surname><given-names>Y</given-names></name><name><surname>Showguchi-Miyata</surname><given-names>J</given-names></name><name><surname>Mizumura</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>J-E</given-names></name></person-group><article-title>ALS2CL, the novel protein highly homologous to the carboxy-terminal half of ALS2, binds to Rab5 and modulates endosome dynamics</article-title><source>FEBS Lett.</source><year>2004</year><volume>575</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">15388334</pub-id></element-citation></ref><ref id="gks615-B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manser</surname><given-names>C</given-names></name><name><surname>Stevenson</surname><given-names>A</given-names></name><name><surname>Banner</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Tudor</surname><given-names>EL</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Nigel~Leigh</surname><given-names>P</given-names></name><name><surname>McLoughlin</surname><given-names>DM</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Miller</surname><given-names>CCJ</given-names></name></person-group><article-title>Deregulation of PKN1 activity disrupts neurofilament organisation and axonal transport</article-title><source>FEBS Lett.</source><year>2008</year><volume>582</volume><fpage>2303</fpage><lpage>2308</lpage><pub-id pub-id-type="pmid">18519042</pub-id></element-citation></ref><ref id="gks615-B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrell-Pags</surname><given-names>M</given-names></name><name><surname>Zala</surname><given-names>D</given-names></name><name><surname>Humbert</surname><given-names>S</given-names></name><name><surname>Saudou</surname><given-names>F</given-names></name></person-group><article-title>Huntingtons disease: from huntingtin function and dysfunction to therapeutic strategies</article-title><source>Cell. Mol. Life Sci.</source><year>2006</year><volume>63</volume><fpage>2642</fpage><lpage>2660</lpage><comment>10.1007/s00018-006-6242-0</comment><pub-id pub-id-type="pmid">17041811</pub-id></element-citation></ref><ref id="gks615-B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peoc'h</surname><given-names>K</given-names></name><name><surname>Gu&#x000e9;rin</surname><given-names>C</given-names></name><name><surname>Brandel</surname><given-names>J</given-names></name><name><surname>Launay</surname><given-names>J</given-names></name><name><surname>Laplanche</surname><given-names>J</given-names></name></person-group><article-title>First report of polymorphisms in the prion-like protein gene (PRND): implications for human prion diseases</article-title><source>Neurosc. lett.</source><year>2000</year><volume>286</volume><fpage>144</fpage><lpage>148</lpage></element-citation></ref><ref id="gks615-B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Berends</surname><given-names>M</given-names></name><name><surname>Post</surname><given-names>J</given-names></name><name><surname>Mensink</surname><given-names>R</given-names></name><name><surname>Verlind</surname><given-names>E</given-names></name><name><surname>Van Der Sluis</surname><given-names>T</given-names></name><name><surname>Kempinga</surname><given-names>C</given-names></name><name><surname>Sijmons</surname><given-names>R</given-names></name><name><surname>Van Der Zee</surname><given-names>A</given-names></name><name><surname>Hollema</surname><given-names>H</given-names></name><etal/></person-group><article-title>Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms</article-title><source>Gastroenterology</source><year>2001</year><volume>120</volume><fpage>1580</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">11375940</pub-id></element-citation></ref><ref id="gks615-B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Hanafusa</surname><given-names>H</given-names></name><name><surname>Ouchida</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Aoe</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Nakachi</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name></person-group><article-title>Single nucleotide polymorphisms in the EXO1 gene and risk of colorectal cancer in a Japanese population</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><fpage>411</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">15550454</pub-id></element-citation></ref><ref id="gks615-B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaklamani</surname><given-names>V</given-names></name><name><surname>Wisinski</surname><given-names>K</given-names></name><name><surname>Sadim</surname><given-names>M</given-names></name><name><surname>Gulden</surname><given-names>C</given-names></name><name><surname>Do</surname><given-names>A</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Baron</surname><given-names>J</given-names></name><name><surname>Ahsan</surname><given-names>H</given-names></name><name><surname>Mantzoros</surname><given-names>C</given-names></name><name><surname>Pasche</surname><given-names>B</given-names></name></person-group><article-title>Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk</article-title><source>JAMA</source><year>2008</year><volume>300</volume><fpage>1523</fpage><pub-id pub-id-type="pmid">18827209</pub-id></element-citation></ref><ref id="gks615-B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byeon</surname><given-names>J-S</given-names></name><name><surname>Jeong</surname><given-names>J-Y</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>S-M</given-names></name><name><surname>Nam</surname><given-names>W-H</given-names></name><name><surname>Myung</surname><given-names>S-J</given-names></name><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Yang</surname><given-names>S-K</given-names></name><name><surname>Kim</surname><given-names>J-H</given-names></name><name><surname>Suh</surname><given-names>DJ</given-names></name></person-group><article-title>Adiponectin and adiponectin receptor in relation to colorectal cancer progression</article-title><source>Inte. J. Cancer</source><year>2010</year><volume>127</volume><fpage>2758</fpage><lpage>2767</lpage></element-citation></ref><ref id="gks615-B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieber</surname><given-names>O</given-names></name><name><surname>Lipton</surname><given-names>L</given-names></name><name><surname>Crabtree</surname><given-names>M</given-names></name><name><surname>Heinimann</surname><given-names>K</given-names></name><name><surname>Fidalgo</surname><given-names>P</given-names></name><name><surname>Phillips</surname><given-names>R</given-names></name><name><surname>Bisgaard</surname><given-names>M</given-names></name><name><surname>Orntoft</surname><given-names>T</given-names></name><name><surname>Aaltonen</surname><given-names>L</given-names></name><name><surname>Hodgson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH</article-title><source>New Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>791</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">12606733</pub-id></element-citation></ref><ref id="gks615-B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Jong</surname><given-names>A</given-names></name><name><surname>Van Puijenbroek</surname><given-names>M</given-names></name><name><surname>Hendriks</surname><given-names>Y</given-names></name><name><surname>Tops</surname><given-names>C</given-names></name><name><surname>Wijnen</surname><given-names>J</given-names></name><name><surname>Ausems</surname><given-names>M</given-names></name><name><surname>Meijers-Heijboer</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Van Os</surname><given-names>T</given-names></name><name><surname>Br&#x000f6;cker-Vriends</surname><given-names>A</given-names></name><etal/></person-group><article-title>Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer</article-title><source>Clin. Cancer Res.</source><year>2004</year><volume>10</volume><fpage>972</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">14871975</pub-id></element-citation></ref><ref id="gks615-B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beiner</surname><given-names>ME</given-names></name><name><surname>Finch</surname><given-names>A</given-names></name><name><surname>Rosen</surname><given-names>B</given-names></name><name><surname>Lubinski</surname><given-names>J</given-names></name><name><surname>Moller</surname><given-names>P</given-names></name><name><surname>Ghadirian</surname><given-names>P</given-names></name><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name></person-group><article-title>The risk of endometrial cancer in women with brca1 and brca2 mutations. a prospective study</article-title><source>Gynecol. Oncol.</source><year>2007</year><volume>104</volume><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16962648</pub-id></element-citation></ref><ref id="gks615-B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>KH</given-names></name><name><surname>Sung</surname><given-names>YH</given-names></name><name><surname>Yang</surname><given-names>MH</given-names></name><name><surname>Jeon</surname><given-names>JO</given-names></name><name><surname>Yook</surname><given-names>YJ</given-names></name><name><surname>Woo</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>H-W</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name></person-group><article-title>Inactivation of Mxi1 induces Il-8 secretion activation in polycystic kidney</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2007</year><volume>356</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17350592</pub-id></element-citation></ref><ref id="gks615-B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname><given-names>K</given-names></name><name><surname>Bihani</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>Y-M</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Ip</surname><given-names>C</given-names></name></person-group><article-title>Enhanced selenium effect on growth arrest by BiP//GRP78 knockdown in p53-null human prostate cancer cells</article-title><source>Oncogene</source><year>2005</year><volume>25</volume><fpage>546</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">16205645</pub-id></element-citation></ref><ref id="gks615-B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y-M</given-names></name><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Kung</surname><given-names>H-J</given-names></name></person-group><article-title>Signal Pathways in Up-regulation of Chemokines by Tyrosine Kinase MER/NYK in Prostate Cancer Cells</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>7311</fpage><lpage>7320</lpage><pub-id pub-id-type="pmid">15492251</pub-id></element-citation></ref><ref id="gks615-B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Keller</surname><given-names>ET</given-names></name><name><surname>Parsons</surname><given-names>SJ</given-names></name><name><surname>Hu</surname><given-names>C-D</given-names></name></person-group><article-title>Ionizing Radiation Induces Prostate Cancer Neuroendocrine Differentiation through Interplay of CREB and ATF2: Implications for Disease Progression</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>9663</fpage><lpage>9670</lpage><pub-id pub-id-type="pmid">19047143</pub-id></element-citation></ref><ref id="gks615-B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Whitfield</surname><given-names>ML</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Brooks</surname><given-names>JD</given-names></name></person-group><article-title>Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer Cells</article-title><source>Mol. Biol. Cell.</source><year>2004</year><volume>15</volume><fpage>506</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">14617803</pub-id></element-citation></ref><ref id="gks615-B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streit</surname><given-names>S</given-names></name><name><surname>Mestel</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Berking</surname><given-names>C</given-names></name></person-group><article-title>FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients</article-title><source>Brit. Jo. cancer</source><year>2006</year><volume>94</volume><fpage>1879</fpage><lpage>1886</lpage></element-citation></ref><ref id="gks615-B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gartside</surname><given-names>M</given-names></name><name><surname>Curtis</surname><given-names>A</given-names></name><name><surname>Yudt</surname><given-names>L</given-names></name><name><surname>Harper</surname><given-names>U</given-names></name><name><surname>Bengston</surname><given-names>A</given-names></name><name><surname>Pavey</surname><given-names>S</given-names></name><name><surname>Tuthill</surname><given-names>R</given-names></name><name><surname>Bastian</surname><given-names>B</given-names></name><name><surname>Meltzer</surname><given-names>P</given-names></name><name><surname>Pollock</surname><given-names>P</given-names></name></person-group><source>AACR Meeting Abstracts</source><year>2005</year><volume>2005</volume><fpage>608</fpage></element-citation></ref><ref id="gks615-B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloethner</surname><given-names>S</given-names></name><name><surname>Mould</surname><given-names>A</given-names></name><name><surname>Stark</surname><given-names>M</given-names></name><name><surname>Hayward</surname><given-names>N</given-names></name></person-group><article-title>Identification of arhgef17, dennd2d, fgfr3, and rb1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay</article-title><source>Genes, Chromosomes and Cancer</source><year>2008</year><volume>47</volume><fpage>1076</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">18677770</pub-id></element-citation></ref><ref id="gks615-B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloethner</surname><given-names>S</given-names></name><name><surname>Mould</surname><given-names>A</given-names></name><name><surname>Stark</surname><given-names>M</given-names></name><name><surname>Hayward</surname><given-names>NK</given-names></name></person-group><article-title>Identification of arhgef17, dennd2d, fgfr3, and rb1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay</article-title><source>Genes, Chromosomes and Cancer</source><year>2008</year><volume>47</volume><fpage>1076</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">18677770</pub-id></element-citation></ref><ref id="gks615-B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koed</surname><given-names>K</given-names></name><name><surname>Wiuf</surname><given-names>C</given-names></name><name><surname>Christensen</surname><given-names>L</given-names></name><name><surname>Wikman</surname><given-names>F</given-names></name><name><surname>Zieger</surname><given-names>K</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>K</given-names></name><name><surname>von~der Maase</surname><given-names>H</given-names></name><name><surname>&#x000d8;rntoft</surname><given-names>T</given-names></name></person-group><article-title>High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>34</fpage><pub-id pub-id-type="pmid">15665277</pub-id></element-citation></ref><ref id="gks615-B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buytaert</surname><given-names>E</given-names></name><name><surname>Matroule</surname><given-names>JY</given-names></name><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Close</surname><given-names>P</given-names></name><name><surname>Kocanova</surname><given-names>S</given-names></name><name><surname>Vandenheede</surname><given-names>JR</given-names></name><name><surname>de Witte</surname><given-names>PA</given-names></name><name><surname>Piette</surname><given-names>J</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name></person-group><article-title>Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells</article-title><source>Oncogene</source><year>2007</year><volume>27</volume><fpage>1916</fpage><lpage>1929</lpage><pub-id pub-id-type="pmid">17952126</pub-id></element-citation></ref><ref id="gks615-B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Blanco</surname><given-names>E</given-names></name><name><surname>Bruns</surname><given-names>I</given-names></name><name><surname>Neumann</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>JC</given-names></name><name><surname>Graef</surname><given-names>T</given-names></name><name><surname>Rosskopf</surname><given-names>M</given-names></name><name><surname>Brors</surname><given-names>B</given-names></name><name><surname>Pechtel</surname><given-names>S</given-names></name><name><surname>Bork</surname><given-names>S</given-names></name><name><surname>Koch</surname><given-names>A</given-names></name><etal/></person-group><article-title>Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>494</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">17252012</pub-id></element-citation></ref><ref id="gks615-B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steelman</surname><given-names>LS</given-names></name><name><surname>Franklin</surname><given-names>RA</given-names></name><name><surname>Abrams</surname><given-names>SL</given-names></name><name><surname>Chappell</surname><given-names>W</given-names></name><name><surname>Kempf</surname><given-names>CR</given-names></name><name><surname>Basecke</surname><given-names>J</given-names></name><name><surname>Stivala</surname><given-names>F</given-names></name><name><surname>Donia</surname><given-names>M</given-names></name><name><surname>Fagone</surname><given-names>P</given-names></name><name><surname>Nicoletti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy</article-title><source>Leukemia</source><year>2011</year><volume>25</volume><fpage>1080</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">21494257</pub-id></element-citation></ref><ref id="gks615-B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name></person-group><article-title>Role of gene-expression profiling in chronic myeloid leukemia</article-title><source>Expert Rev. Hematol.</source><year>2009</year><volume>2</volume><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">21082998</pub-id></element-citation></ref><ref id="gks615-B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Gu</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><etal/></person-group><article-title>Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia</article-title><source>Proc. Nat. Acad. Sci.</source><year>2008</year><volume>105</volume><fpage>2076</fpage><pub-id pub-id-type="pmid">18250304</pub-id></element-citation></ref><ref id="gks615-B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forestier</surname><given-names>E</given-names></name><name><surname>Izraeli</surname><given-names>S</given-names></name><name><surname>Beverloo</surname><given-names>B</given-names></name><name><surname>Haas</surname><given-names>O</given-names></name><name><surname>Pession</surname><given-names>A</given-names></name><name><surname>Michalov&#x000e1;</surname><given-names>K</given-names></name><name><surname>Stark</surname><given-names>B</given-names></name><name><surname>Harrison</surname><given-names>C</given-names></name><name><surname>Teigler-Schlegel</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name></person-group><article-title>Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>1575</fpage><pub-id pub-id-type="pmid">17971484</pub-id></element-citation></ref><ref id="gks615-B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valk</surname><given-names>P</given-names></name><name><surname>Verhaak</surname><given-names>R</given-names></name><name><surname>Beijen</surname><given-names>M</given-names></name><name><surname>Erpelinck</surname><given-names>C</given-names></name><name><surname>van Doorn-Khosrovani</surname><given-names>S</given-names></name><name><surname>Boer</surname><given-names>J</given-names></name><name><surname>Beverloo</surname><given-names>H</given-names></name><name><surname>Moorhouse</surname><given-names>M</given-names></name><name><surname>van~der Spek</surname><given-names>P</given-names></name><name><surname>L&#x000f6;wenberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>Prognostically useful gene-expression profiles in acute myeloid leukemia</article-title><source>New Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>1617</fpage><lpage>1628</lpage><pub-id pub-id-type="pmid">15084694</pub-id></element-citation></ref><ref id="gks615-B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozman</surname><given-names>M</given-names></name><name><surname>Cam&#x000f3;s</surname><given-names>M</given-names></name><name><surname>Colomer</surname><given-names>D</given-names></name><name><surname>Villamor</surname><given-names>N</given-names></name><name><surname>Esteve</surname><given-names>J</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Carri&#x000f3;</surname><given-names>A</given-names></name><name><surname>Aymerich</surname><given-names>M</given-names></name><name><surname>Aguilar</surname><given-names>J</given-names></name><name><surname>Domingo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t (8; 16)(p11; p13) translocation</article-title><source>Genes Chromosomes Cancer</source><year>2004</year><volume>40</volume><fpage>140</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">15101047</pub-id></element-citation></ref><ref id="gks615-B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>p53 and its downstream proteins as molecular targets of cancer</article-title><source>Mol. Carcinogenesis</source><year>2006</year><volume>45</volume><fpage>409</fpage><lpage>415</lpage></element-citation></ref><ref id="gks615-B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Barton</surname><given-names>J</given-names></name><name><surname>Blackstad</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name></person-group><article-title>LATS1 tumor suppressor regulates G2/M transition and apoptosis</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>1233</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">11850843</pub-id></element-citation></ref><ref id="gks615-B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altucci</surname><given-names>L</given-names></name><name><surname>Leibowitz</surname><given-names>MD</given-names></name><name><surname>Ogilvie</surname><given-names>KM</given-names></name><name><surname>de Lera</surname><given-names>AR</given-names></name><name><surname>Gronemeyer</surname><given-names>H</given-names></name></person-group><article-title>RAR and RXR modulation in cancer and metabolic disease</article-title><source>Nat Rev Drug Discov</source><year>2007</year><volume>6</volume><fpage>793</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">17906642</pub-id></element-citation></ref><ref id="gks615-B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>G1 cell-cycle control and cancer</article-title><source>Nature</source><year>2004</year><volume>432</volume><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">15549091</pub-id></element-citation></ref><ref id="gks615-B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>KM</given-names></name><name><surname>Poon</surname><given-names>FF</given-names></name><name><surname>Wong</surname><given-names>SCC</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name></person-group><article-title>WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer</article-title><source>Clin Cancer Res.</source><year>2008</year><volume>14</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">18172252</pub-id></element-citation></ref><ref id="gks615-B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streit</surname><given-names>S</given-names></name><name><surname>Mestel</surname><given-names>DS</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Berking</surname><given-names>C</given-names></name></person-group><article-title>FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><fpage>1879</fpage><lpage>1886</lpage><pub-id pub-id-type="pmid">16721364</pub-id></element-citation></ref><ref id="gks615-B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Cancer genes and the pathways they control</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">15286780</pub-id></element-citation></ref><ref id="gks615-B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>CJ</given-names></name><name><surname>Lain</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>CS</given-names></name><name><surname>Fersht</surname><given-names>AR</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name></person-group><article-title>Awakening guardian angels: drugging the p53 pathway</article-title><source>Nat. Rev. Cancer</source><year>2009</year><volume>9</volume><fpage>862</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">19935675</pub-id></element-citation></ref><ref id="gks615-B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citri</surname><given-names>A</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><article-title>EGF-ERBB signalling: towards the systems level</article-title><source>Nat. Rev. Mole. Cell Biol.</source><year>2006</year><volume>7</volume><fpage>505</fpage><lpage>516</lpage></element-citation></ref><ref id="gks615-B140"><label>140</label><element-citation publication-type="book"><comment>(2006) Targeting the Hedgehog pathway in cancer. <italic>Nature Reviews Drug Discovery</italic>, <bold>5</bold>, 1026&#x02013;1033</comment></element-citation></ref><ref id="gks615-B141"><label>141</label><element-citation publication-type="book"><comment>(2005) Promoting apoptosis as a strategy for cancer drug discovery. <italic>Nat. Rev. Cancer</italic>, <bold>5</bold>, 876&#x02013;885</comment></element-citation></ref><ref id="gks615-B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsankova</surname><given-names>N</given-names></name><name><surname>Renthal</surname><given-names>W</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><source>Epigenetic regulation in psychiatric disorders</source><year>2007</year><volume>8</volume><fpage>355</fpage><lpage>367</lpage></element-citation></ref><ref id="gks615-B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarubin</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>J</given-names></name></person-group><article-title>Activation and signaling of the p38 MAP kinase pathway</article-title><source>Cell Res.</source><year>2005</year><volume>15</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">15686620</pub-id></element-citation></ref><ref id="gks615-B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoehndorf</surname><given-names>R</given-names></name><name><surname>Schofield</surname><given-names>P</given-names></name><name><surname>Gkoutos</surname><given-names>G</given-names></name></person-group><article-title>PhenomeNET: a whole-phenome approach to disease gene discovery</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><fpage>e119</fpage><pub-id pub-id-type="pmid">21737429</pub-id></element-citation></ref><ref id="gks615-B145"><label>145</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><source>KDD '09: Proceedings of the 15th ACM SIGKDD international conference on Knowledge discovery and data mining</source><year>2009</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>ACM</publisher-name><fpage>359</fpage><lpage>368</lpage></element-citation></ref></ref-list></back></article>